

Phytozon® Studies

Ingredient: RNI 249® - Works Cited

(1) Andrews K, Grunebaum AN: Composition and method for fertility therapy using nutritional supplements. USPTO No. 8,663,709. 2014 Mar 4.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetacgi%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,663,709.PN.&OS=PN/8,663,709&RS=PN/8,663,709>

(2) Zhang Y, Yu L, Jin W, Ao M: Effect of ethanolic extract of *Lepidium meyenii* Walp on serum hormone levels in ovariectomized rats. *Indian J Pharmacol.* 2014 Jul;46(4):416-9. <http://www.ncbi.nlm.nih.gov/pubmed/25097281>

(3) Zha S, Zhao Q, Chen J et al: Extraction, purification and antioxidant activities of the polysaccharides from maca (*Lepidium meyenii*). *Carbohydr Polym.* 2014 Oct 13;111:584-7.

<http://www.ncbi.nlm.nih.gov/pubmed/25037390>

(4) Hajdu Z, Nicolussi S, Rau M et al: Identification of Endocannabinoid System-Modulating N-Alkylamides from *Heliopsis helianthoides* var. *scabra* and *Lepidium meyenii*. *J Nat Prod.* 2014 Jul 25;77(7):1663-9.

<http://www.ncbi.nlm.nih.gov/pubmed/24972328>

(5) Stojanovska L, Law C, Lai B et al: Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. *Climacteric.* 2014 Aug 7:1-10. <http://www.ncbi.nlm.nih.gov/pubmed/24931003>

(6) Ai Z, Cheng AF, Yu YT et al: Antidepressant-like behavioral, anatomical, and biochemical effects of petroleum ether extract from maca (*Lepidium meyenii*) in mice exposed to chronic unpredictable mild stress. *J Med Food.* 2014 May;17(5):535-42.

<http://www.ncbi.nlm.nih.gov/pubmed/24730393>

(7) Benites Goñi HE, Cok García J, Bussalleu Cavero A et al: Assessing the effect of *Lepidium meyenii* "Maca" on the gastric mucosa in patients with functional dyspepsia. *Rev Gastroenterol Peru.* 2014 Jan-Mar;34(1):39-43 (Spanish).

<http://www.ncbi.nlm.nih.gov/pubmed/24721957>

- (8) Gonzales GF, Villaorduña L, Gasco M, Rubio J et al: Maca (*Lepidium meyenii* Walp), a review of its biological properties. *Rev Peru Med Exp Salud Publica*. 2014;31(1):100-10 (Spanish).
<http://www.ncbi.nlm.nih.gov/pubmed/24718534>
- (9) Lembè DM, Gasco M, Gonzales GF: Synergistic effect of the hydroalcoholic extract from *Lepidium meyenii* (Brassicaceae) and *Fagara tessmannii* (Rutaceae) on male sexual organs and hormone level in rats. *Pharmacognosy Res*. 2014 Jan;6(1):80-6. <http://www.ncbi.nlm.nih.gov/pubmed/24497748>
- (10) Uchiyama F, Jikyo T, Takeda R et al: *Lepidium meyenii* (Maca) enhances the serum levels of luteinising hormone in female rats. *J Ethnopharmacol*. 2014 Feb 3;151(2):897-902. <http://www.ncbi.nlm.nih.gov/pubmed/24333960>
- (11) Gonzales GF, Gasco M, Lozada-Requena I: Role of maca (*Lepidium meyenii*) consumption on serum interleukin-6 levels and health status in populations living in the Peruvian Central Andes over 4000 m of altitude. *Plant Foods Hum Nutr*. 2013 Dec;68(4):347-51.
<http://www.ncbi.nlm.nih.gov/pubmed/23934543>
- (12) Wu H, Kelley CJ, Pino-Figueroa A et al: Macamides and their synthetic analogs: evaluation of in vitro FAAH inhibition. *Bioorg Med Chem*. 2013 Sep 1;21(17):5188-97. <http://www.ncbi.nlm.nih.gov/pubmed/23891163>
- (13) Almukadi H, Wu H, Böhlke M et al: The macamide N-3-methoxybenzyl-linoleamide is a time-dependent fatty acid amide hydrolase (FAAH) inhibitor. *Mol Neurobiol*. 2013 Oct;48(2):333-9.
<http://www.ncbi.nlm.nih.gov/pubmed/23853040>
- (14) Gonzales GF, Vasquez VB, Gasco M: The transillumination technique as a method for the assessment of spermatogenesis using medicinal plants: the effect of extracts of black maca (*Lepidium meyenii*) and camu camu (*Myrciaria dubia*) on stages of the spermatogenic cycle in male rats. *Toxicol Mech Methods*. 2013 Oct;23(8):559-65.
<http://www.ncbi.nlm.nih.gov/pubmed/23650963>
- (15) Gonzales GF, Gonzales-Castañeda C, Gasco M: A mixture of extracts from Peruvian plants (black maca and yacon) improves sperm count and reduced

glycemia in mice with streptozotocin-induced diabetes. *Toxicol Mech Methods*. 2013 Sep;23(7):509-18.

<http://www.ncbi.nlm.nih.gov/pubmed/23489070>

(16) Shrivastava A, Gupta VB: Various treatment options for benign prostatic hyperplasia: A current update. *J Midlife Health*. 2012 Jan;3(1):10-9.

<http://www.ncbi.nlm.nih.gov/pubmed/22923974>

(17) Clément C, Witschi U, Kreuzer M: The potential influence of plant-based feed supplements on sperm quantity and quality in livestock: a review. *Anim Reprod Sci*. 2012 May;132(1-2):1-10.

<http://www.ncbi.nlm.nih.gov/pubmed/22575847>

(18) Bobrowski, PJ: Methods and compositions to enhance endogenous IGF production and their use. USPTO No. 8182847: 2012 May 22.

<http://patft.uspto.gov/netacgi/nph->

[Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fmetahtml%2FPTO%2Fsearch-bool.html&r=11&f=G&l=50&co1=AND&d=PTXT&s1=Paul&s2=Bobrowski&OS=Paul+AND+Bobrowski&RS=Paul+AND+Bobrowski](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fmetahtml%2FPTO%2Fsearch-bool.html&r=11&f=G&l=50&co1=AND&d=PTXT&s1=Paul&s2=Bobrowski&OS=Paul+AND+Bobrowski&RS=Paul+AND+Bobrowski)

(19) Gonzales GF: Ethnobiology and Ethnopharmacology of *Lepidium meyenii* (Maca), a Plant from the Peruvian Highlands. *Evid Based Complement Alternat Med*. 2012; 2012:193496.

<http://www.ncbi.nlm.nih.gov/pubmed/21977053>

(20) Zhao J, Avula B, Chan M et al: Metabolomic differentiation of maca (*Lepidium meyenii*) accessions cultivated under different conditions using NMR and chemometric analysis. *Planta Med*. 2012 Jan;78(1):90-101.

<http://www.ncbi.nlm.nih.gov/pubmed/21858755>

(21) Bobrowski P: Methods and compositions to enhance endogenous IGF production and their uses. USPTO 8,182,847: May 22, 2012.

(22) Akhtar N, Miller MJ, Haqqi TM: Effect of a Herbal-Leucine mix on the IL-1 β -induced cartilage degradation and inflammatory gene expression in human chondrocytes. *BMC Complement Altern Med*. 2011 Aug 19;11:66.

<http://www.ncbi.nlm.nih.gov/pubmed/21854562>

(23) Lee MS, Shin BC, Yang EJ et al: Maca (*Lepidium meyenii*) for treatment of menopausal symptoms: A systematic review. *Maturitas*. 2011 Nov;70(3):227-33. <http://www.ncbi.nlm.nih.gov/pubmed/21840656>

(24) Gonzales-Castañeda C, Rivera V, Chirinos AL et al: Photoprotection against the UVB-induced oxidative stress and epidermal damage in mice using leaves of three different varieties of *Lepidium meyenii* (maca).

(25) *Int J Dermatol*. 2011 Aug;50(8):928-38.
<http://www.ncbi.nlm.nih.gov/pubmed/21781063>

(26) Rubio J, Yucra S, Gasco M et al: Dose-response effect of black maca (*Lepidium meyenii*) in mice with memory impairment induced by ethanol. *Toxicol Mech Methods*. 2011 Oct;21(8):628-34.
<http://www.ncbi.nlm.nih.gov/pubmed/21780878>

(27) Rubio J, Qiong W, Liu X et al: Aqueous Extract of Black Maca (*Lepidium meyenii*) on Memory Impairment Induced by Ovariectomy in Mice. *Evid Based Complement Alternat Med*. 2011;2011:253958.
<http://www.ncbi.nlm.nih.gov/pubmed/18955369>

(28) Gonzales C, Leiva-Revilla J, Rubio J et al: Effect of red maca (*Lepidium meyenii*) on prostate zinc levels in rats with testosterone-induced prostatic hyperplasia. *Andrologia*. 2012 May;44 Suppl 1:362-9.
<http://www.ncbi.nlm.nih.gov/pubmed/21762188>

(29) Clément C, Diaz Grados DA, Avula B et al: Influence of colour type and previous cultivation on secondary metabolites in hypocotyls and leaves of maca (*Lepidium meyenii* Walpers). *J Sci Food Agric*. 2010 Apr 15;90(5):861-9.
<http://www.ncbi.nlm.nih.gov/pubmed/20355123>

(30) Mazaro-Costa R, Andersen ML, Hachul H, Tufik S.: Medicinal plants as alternative treatments for female sexual dysfunction: utopian vision or possible treatment in climacteric women? *J Sex Med*. 2010 Nov; 7(11):3695-714. <http://www.ncbi.nlm.nih.gov/pubmed/20722793>

(31) Zheng BL, He K, Shao Y et al: Compositions and methods for their preparation from *lepidium*. USPTO No. RE43,005. 2001 Dec 6.
<http://patft.uspto.gov/netacgi/nph->

[Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fmetahtml%2FPTO%2Fsearch-bool.html&r=11&f=G&l=50&co1=AND&d=PTXT&s1=Lepidium&s2=meyenii&O=S=Lepidium+AND+meyenii&RS=Lepidium+AND+meyenii](http://www.ncbi.nlm.nih.gov/pubmed/20633111)

(32) Pino-Figueroa A, Nguyen D, Maher TJ: Neuroprotective effects of *Lepidium meyenii* (Maca). *Ann N Y Acad Sci*. 2010 Jun;1199:77-85.
<http://www.ncbi.nlm.nih.gov/pubmed/20633111>

(33) Ranilla LG, Kwon YI, Apostolidis E et al: Phenolic compounds, antioxidant activity and in vitro inhibitory potential against key enzymes relevant for hyperglycemia and hypertension of commonly used medicinal plants, herbs and spices in Latin America. *Bioresour Technol*. 2010 Jun;101(12):4676-89.
<http://www.ncbi.nlm.nih.gov/pubmed/20185303>

(34) Clément C, Kneubühler J, Urwyler A et al: Effect of maca supplementation on bovine sperm quantity and quality followed over two spermatogenic cycles. *Theriogenology*. 2010 Jul 15;74(2):173-83.
<http://www.ncbi.nlm.nih.gov/pubmed/20452008>

(35) Shin BC, Lee MS, Yang EJ et al: Maca (*L. meyenii*) for improving sexual function: a systematic review. *BMC Complement Altern Med*. 2010 Aug 6;10:44. <http://www.ncbi.nlm.nih.gov/pubmed/20691074>

(36) Gonzales C, Cárdenas-Valencia I, Leiva-Revilla J et al: Effects of different varieties of Maca (*Lepidium meyenii*) on bone structure in ovariectomized rats. *Forsch Komplementmed*. 2010;17(3):137-43.
<http://www.ncbi.nlm.nih.gov/pubmed/20616517>

(37) Gonzales GF, Gonzales C, Gonzales-Castañeda C: *Lepidium meyenii* (Maca): a plant from the highlands of Peru--from tradition to science. *Forsch Komplementmed*. 2009 Dec;16(6):373-80.
<http://www.ncbi.nlm.nih.gov/pubmed/20090350>

(38) Stone M, Ibarra A, Roller M et al: A pilot investigation into the effect of maca supplementation on physical activity and sexual desire in sportsmen. *J Ethnopharmacol*. 2009 Dec 10;126(3):574-6.
<http://www.ncbi.nlm.nih.gov/pubmed/19781622>

- (39) Zenico T, Cicero AF, Valmorri L et al: Subjective effects of *Lepidium meyenii* (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomized, double-blind clinical trial. *Andrologia*. 2009 Apr;41(2):95-9.
<http://www.ncbi.nlm.nih.gov/pubmed/19260845>
- (40) Gonzales-Castañeda C, Gonzales GF: Hypocotyls of *Lepidium meyenii* (maca), a plant of the Peruvian highlands, prevent ultraviolet A-, B-, and C-induced skin damage in rats. *Photodermatol Photoimmunol Photomed*. 2008 Feb;24(1):24-31. <http://www.ncbi.nlm.nih.gov/pubmed/18201354>
- (41) Valentová K, Stejskal D, Bartek J et al: Maca (*Lepidium meyenii*) and yacon (*Smallanthus sonchifolius*) in combination with silymarin as food supplements: in vivo safety assessment. *Food Chem Toxicol*. 2008 Mar;46(3):1006-13. <http://www.ncbi.nlm.nih.gov/pubmed/18054420>
- (42) Gonzales GF, Gasco M, Malheiros-Pereira A et al: Antagonistic effect of *Lepidium meyenii* (red maca) on prostatic hyperplasia in adult mice. *Andrologia*. 2008 Jun;40(3):179-85.
<http://www.ncbi.nlm.nih.gov/pubmed/18477205>
- (43) Dording CM, Fisher L, Papakostas G et al: A double-blind, randomized, pilot dose-finding study of maca root (*L. meyenii*) for the management of SSRI-induced sexual dysfunction. *CNS Neurosci Ther*. 2008 Fall;14(3):182-91.
<http://www.ncbi.nlm.nih.gov/pubmed/18801111>
- (44) Brooks NA, Wilcox G, Walker KZ et al: Beneficial effects of *Lepidium meyenii* (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. *Menopause*. 2008 Nov-Dec;15(6):1157-62.
<http://www.ncbi.nlm.nih.gov/pubmed/18784609>
- (45) Wang Y, Wang Y, McNeil B et al: Maca: An Andean Crop with multi-pharmacological functions. *Food Res Inter*. 2007 40:783-92.
<http://wenku.baidu.com/view/3c037f18c5da50e2524d7f5e>
- (46) Lentz A, Gravitt K, Carson CC et al: Acute and chronic dosing of *Lepidium meyenii* (Maca) on male rat sexual behavior. *J Sex Med*. 2007 Mar;4(2):332-9; discussion 339-40. <http://www.ncbi.nlm.nih.gov/pubmed/17367428>

- (47) Yucra S, Gasco M, Rubio J et al: Effect of different fractions from hydroalcoholic extract of Black Maca (*Lepidium meyenii*) on testicular function in adult male rats. *Fertil Steril*. 2008 May;89(5 Suppl):1461-7. Epub 2007 Jul 31. <http://www.ncbi.nlm.nih.gov/pubmed/17669402>
- (48) Vecera R, Orolin J, Skottová N et al: The influence of maca (*Lepidium meyenii*) on antioxidant status, lipid and glucose metabolism in rat. *Plant Foods Hum Nutr*. 2007 Jun;62(2):59-63. <http://www.ncbi.nlm.nih.gov/pubmed/17333395>
- (49) Gasco M, Aguilar J, Gonzales GF: Effect of chronic treatment with three varieties of *Lepidium meyenii* (Maca) on reproductive parameters and DNA quantification in adult male rats. *Andrologia*. 2007 Aug;39(4):151-8. <http://www.ncbi.nlm.nih.gov/pubmed/17683465>
- (50) Gasco M, Villegas L, Yucra S, Rubio J et al: Dose-response effect of Red Maca (*Lepidium meyenii*) on benign prostatic hyperplasia induced by testosterone enanthate. *Phytomedicine*. 2007 Aug;14(7-8):460-4. <http://www.ncbi.nlm.nih.gov/pubmed/17289361>
- (51) Rubio J, Dang H, Gong M et al: Aqueous and hydroalcoholic extracts of Black Maca (*Lepidium meyenii*) improve scopolamine-induced memory impairment in mice. *Food Chem Toxicol*. 2007 Oct;45(10):1882-90. Epub 2007 Apr 20. <http://www.ncbi.nlm.nih.gov/pubmed/17543435>
- (52) Mehta K, Gala J, Bhasale S et al: Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. *BMC Complement Altern Med*. 2007 Oct 31;7:34. <http://www.ncbi.nlm.nih.gov/pubmed/17974032>
- (53) Gonzales GF, Valerio LG Jr: Medicinal plants from Peru: a review of plants as potential agents against cancer. *Anticancer Agents Med Chem*. 2006 Sep;6(5):429-44 <http://www.ncbi.nlm.nih.gov/pubmed/17017852>
- (54) Gonzales GF, Nieto J, Rubio J, Gasco M: Effect of Black maca (*Lepidium meyenii*) on one spermatogenic cycle in rats. *Andrologia*. 2006 Oct;38(5):166-72. <http://www.ncbi.nlm.nih.gov/pubmed/16961569>

(55) Rubio J, Caldas M, Dávila S et al: Effect of three different cultivars of *Lepidium meyenii* (Maca) on learning and depression in ovariectomized mice. *BMC Complement Altern Med*. 2006 Jun 23;6:23.

<http://www.ncbi.nlm.nih.gov/pubmed/16796734>

(56) Miller MJ, Ahmed S, Bobrowski P et al: The chondroprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. *BMC Complement Altern Med*. 2006 Apr 7;6:13. <http://www.ncbi.nlm.nih.gov/pubmed/16603065>

(57) Valentová K, Buckiová D, Kren V et al: The in vitro biological activity of *Lepidium meyenii* extracts. *Cell Biol Toxicol*. 2006 Mar;22(2):91-9.

<http://www.ncbi.nlm.nih.gov/pubmed/16528448>

(58) Rubio J, Riqueros MI, Gasco M et al: *Lepidium meyenii* (Maca) reversed the lead acetate induced damage on reproductive function in male rats. *Food Chem Toxicol*. 2006 Jul;44(7):1114-22.

<http://www.ncbi.nlm.nih.gov/pubmed/16510228>

(59) Zhang Y, Yu L, Ao M et al: Effect of ethanol extract of *Lepidium meyenii* Walp on osteoporosis in ovariectomized rat. *J Ethnopharmacol*. 2006 Apr 21;105(1-2):274-9.

<http://www.ncbi.nlm.nih.gov/pubmed/16466876>

(60) Bogani P, Simonini F, Iriti M et al: *Lepidium meyenii* (Maca) does not exert direct androgenic activities. *J Ethnopharmacol*. 2006 Apr 6;104(3):415-7.

<http://www.ncbi.nlm.nih.gov/pubmed/16239088>

(61) Gonzales C, Rubio J, Gasco M et al: Effect of short-term and long-term treatments with three ecotypes of *Lepidium meyenii* (MACA) on spermatogenesis in rats. *J Ethnopharmacol*. 2006 Feb 20;103(3):448-54.

<http://www.ncbi.nlm.nih.gov/pubmed/16174556>

(62) Valerio LG Jr, Gonzales GF: Toxicological aspects of the South American herbs cat's claw (*Uncaria tomentosa*) and Maca (*Lepidium meyenii*): a critical synopsis. *Toxicol Rev*. 2005;24(1):11-35. Review.

<http://www.ncbi.nlm.nih.gov/pubmed/16042502>

- (63) Ruiz-Luna AC, Salazar S, Aspajo NJ et al: *Lepidium meyenii* (Maca) increases litter size in normal adult female mice. *Reprod Biol Endocrinol*. 2005 May 3;3:16. <http://www.ncbi.nlm.nih.gov/pubmed/15869705>
- (64) Chung F, Rubio J, Gonzales C et al: Dose-response effects of *Lepidium meyenii* (Maca) aqueous extract on testicular function and weight of different organs in adult rats. *J Ethnopharmacol*. 2005 Apr 8;98(1-2):143-7. <http://www.ncbi.nlm.nih.gov/pubmed/15763375>
- (65) Zhao J, Muhammad I, Dunbar DC et al: New alkaloids from maca (*Lepidium meyenii*). *J Agric Food Chem*. 2005 Feb 9;53(3):690-3. <http://www.ncbi.nlm.nih.gov/pubmed/15686421>
- (66) Bustos-Obregon E, Yucra S et al: *Lepidium meyenii* (Maca) reduces spermatogenic damage induced by a single dose of malathion in mice. *Asian J Androl*. 2005 Mar;7(1):71-6. <http://www.ncbi.nlm.nih.gov/pubmed/15685355>
- (67) Cui B, Zheng B, He K et al: Imidazole alkaloids from *Lepidium meyenii* and methods of usage. USPTO No. 6,878,731. 2005 Apr 12. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fmetahtml%2FPTO%2Fsearch-bool.html&r=21&f=G&l=50&co1=AND&d=PTXT&s1=Lepidium&s2=meyenii&OS=Lepidium+AND+meyenii&RS=Lepidium+AND+meyenii>
- (68) Gonzales GF, Miranda S, Nieto J et al: Red maca (*Lepidium meyenii*) reduced 2005 Jan 20;3:5. <http://www.ncbi.nlm.nih.gov/pubmed/15661081>
- (69) Gonzales GF, Gasco M, Córdova A et al: Effect of *Lepidium meyenii* (Maca) on spermatogenesis in male rats acutely exposed to high altitude (4340 m). *J Endocrinol*. 2004 Jan;180(1):87-95. <http://www.ncbi.nlm.nih.gov/pubmed/14709147>
- (70) Bobrowski Paul (PI): Enhanced IGF-1 Production by Human Cartilage. 2004. NIH National Institute on Aging #1R43AG024733-01. http://projectreporter.nih.gov/project_info_description.cfm?aid=6834041&icde=0
- (71) Zheng B, He K, Shao Y et al: Compositions and methods for their preparation from *Lepidium*. USPTO No. 6,552,206. 2003 Apr 22.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearchbool.html&r=22&f=G&l=50&co1=AND&d=PTXT&s1=Lepidium&s2=meyenii&OS=Lepidium+AND+meyenii&RS=Lepidium+AND+meyenii>

(72) Valentová K, Ulrichová J: Smallanthus sonchifolius and Lepidium meyenii - prospective Andean crops for the prevention of chronic diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Dec;147(2):119-30. <http://www.ncbi.nlm.nih.gov/pubmed/15037892>

(73) Gonzales GF, Rubio J, Chung A et al: Effect of alcoholic extract of Lepidium meyenii (Maca) on testicular function in male rats. Asian J Androl. 2003 Dec;5(4):349-52. <http://www.ncbi.nlm.nih.gov/pubmed/14695987>

(74) Comhaire FH, Mahmoud A: The role of food supplements in the treatment of the infertile man. Reprod Biomed Online. 2003 Oct-Nov;7(4):385-91. <http://www.ncbi.nlm.nih.gov/pubmed/14656398>

(75) Oshima M, Gu Y, Tsukada S: Effects of Lepidium meyenii Walp and Jatropha macrantha on blood levels of estradiol-17 beta, progesterone, testosterone and the rate of embryo implantation in mice. J Vet Med Sci. 2003 Oct;65(10):1145-6. <http://www.ncbi.nlm.nih.gov/pubmed/14600359>

(76) Cui B, Zheng BL, He K et al: Imidazole alkaloids from Lepidium meyenii. J Nat Prod. 2003 Aug;66(8):1101-3. <http://www.ncbi.nlm.nih.gov/pubmed/12932133>

(77) Gonzales GF, Córdova A, Vega K et al: Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men. J Endocrinol. 2003 Jan;176(1):163-8. <http://www.ncbi.nlm.nih.gov/pubmed/12525260>

(78) Cicero AF, Piacente S, Plaza A et al: Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia. 2002 Jun;34(3):177-9. <http://www.ncbi.nlm.nih.gov/pubmed/12059814>

(79) Sandoval M, Okuhama NN, Angeles F et al: Antioxidant activity of the cruciferous vegetable Maca (Lepidium meyenii) Food Chemistry 2002. 79:

207-213.

<http://www.sciencedirect.com/science/article/pii/S0308814602001334>

(80) Zheng B, Kim C, Wolthoff S et al: Treatment of sexual dysfunction with an extract of *Lepidium meyenii* roots. USPTO No. 6,428,824. 2002 Aug 6.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetacgi%2FPTO%2Fsearch-bool.html&r=24&f=G&l=50&co1=AND&d=PTXT&s1=Lepidium&s2=meiyenii&OS=Lepidium+AND+meiyenii&RS=Lepidium+AND+meiyenii>

(81) Piacente S, Carbone V, Plaza A et al: Investigation of the tuber constituents of maca (*Lepidium meyenii* Walp.). *J Agric Food Chem.* 2002 Sep 25;50(20):5621-5. <http://www.ncbi.nlm.nih.gov/pubmed/12236688>

(82) Gonzales GF, Córdova A, Vega K et al: Effect of *Lepidium meyenii* (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. *Andrologia.* 2002 Dec;34(6):367-72.

<http://www.ncbi.nlm.nih.gov/pubmed/12472620>

(83) Muhammad I, Zhao J, Dunbar DC et al: Constituents of *Lepidium meyenii* 'maca'. *Phytochemistry.* 2002 Jan;59(1):105-10.

<http://www.ncbi.nlm.nih.gov/pubmed/11754952>

(84) Zheng B, Kim C, Wolthoff S et al: Extract of *Lepidium meyenii* roots for pharmaceutical applications. USPTO No. 6,267,995. 2001 Jul 31.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetacgi%2FPTO%2Fsearch-bool.html&r=25&f=G&l=50&co1=AND&d=PTXT&s1=Lepidium&s2=meiyenii&OS=Lepidium+AND+meiyenii&RS=Lepidium+AND+meiyenii>

(85) Gonzales GF, Cordova A, Gonzales C et al: *Lepidium meyenii* (Maca) improved semen parameters in adult men. *Asian J Androl.* 2001 Dec;3(4):301-3. <http://www.ncbi.nlm.nih.gov/pubmed/11753476>

(86) Gonzales GF, Ruiz A, Gonzales C et al: Effect of *Lepidium meyenii* (maca) roots on spermatogenesis of male rats. *Asian J Androl.* 2001 Sep;3(3):231-3.

<http://www.ncbi.nlm.nih.gov/pubmed/11561196>

(87) Cicero AF, Bandieri E, Arletti R: *Lepidium meyenii* Walp. improves sexual behavior in male rats independently from its action on spontaneous locomotor activity. *J Ethnopharmacol.* 2001 May;75(2-3):225-9.

<http://www.ncbi.nlm.nih.gov/pubmed/11297856>

(88) Canales M, Aguilar J, Prada A et al: Nutritional evaluation of *Lepidium meyenii* (MACA) in albino mice and their descendants. *Arch Latinoam Nutr.* 2000 Jun;50(2):126-33 (Spanish).

<http://www.ncbi.nlm.nih.gov/pubmed/11048583>

(89) Zheng BL, He K, Kim CH et al: Effect of a lipidic extract from *Lepidium meyenii* on sexual behavior in mice and rats. *Urology.* 2000 Apr;55(4):598-602. <http://www.ncbi.nlm.nih.gov/pubmed/10736519>

Ingredient: Vincaria® - Works Cited

(1) Mehta K, Gala J, Bhasale S et al: Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. *BMC Complement Altern Med.* 2007 Oct 31;7:34. <http://www.ncbi.nlm.nih.gov/pubmed/17974032>

(2) Piscoya J, Rodriguez Z, Bustamante SA et al: Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species *Uncaria guianensis*. *Inflamm Res.* 2001 Sep;50(9):442-8.

<http://www.ncbi.nlm.nih.gov/pubmed/11603848>

(3) Miller MJ, Mehta K, Kunte S et al: Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]. *J Inflamm (Lond).* 2005 Oct 21;2:11. <http://www.ncbi.nlm.nih.gov/pubmed/16242032>

(4) Sandoval M, Okuhama NN, Zhang XJ et al: Anti-inflammatory and antioxidant activities of cat's claw (*Uncaria tomentosa* and *Uncaria guianensis*) are independent of their alkaloid content. *Phytomedicine.* 2002 May;9(4):325-37. <http://www.ncbi.nlm.nih.gov/pubmed/12120814>

- (5) J. F. Gmelin, Carvalho MV, Penido C et al: Investigations on the anti-inflammatory and anti-allergic activities of the leaves of *Uncaria guianensis* (Aublet). *Inflammopharmacology*. 2006 Mar;14(1-2):48-56.
<http://www.ncbi.nlm.nih.gov/pubmed/16835713>
- (6) Miller MJ, Ahmed S, Bobrowski P et al: The chondroprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. *BMC Complement Altern Med*. 2006 Apr 7;6:13. <http://www.ncbi.nlm.nih.gov/pubmed/16603065>
- (7) Correia AF, Segovia JF, Gonçalves MC et al: Amazonian plant crude extract screening for activity against multidrug-resistant bacteria. *Eur Rev Med Pharmacol Sci*. 2008 Nov-Dec;12(6):369-80.
<http://www.ncbi.nlm.nih.gov/pubmed/19146199>
- (8) Urdanibia I, Michelangeli F, Ruiz MC et al: Anti-inflammatory and antitumoural effects of *Uncaria guianensis* bark. *J Ethnopharmacol*. 2013 Dec 12;150(3):1154-62. <http://www.ncbi.nlm.nih.gov/pubmed/24212077>
- (9) Dietrich F, Kaiser S, Rockenbach L et al: Quinovic acid glycosides purified fraction from *Uncaria tomentosa* induces cell death by apoptosis in the T24 human bladder cancer cell line. *Food Chem Toxicol*. 2014 May;67:222-9.
<http://www.ncbi.nlm.nih.gov/pubmed/24607820>
- (10) Caon T, Kaiser S, Feltrin C et al: Antimutagenic and antiherpetic activities of different preparations from *Uncaria tomentosa* (cat's claw). *Food Chem Toxicol*. 2014 Apr;66:30-5. <http://www.ncbi.nlm.nih.gov/pubmed/24447975>
- (11) Lima-Junior RS, Mello Cda S, Siani AC et al: *Uncaria tomentosa* alkaloidal fraction reduces paracellular permeability, IL-8 and NS1 production on human microvascular endothelial cells infected with dengue virus. *Nat Prod Commun*. 2013 Nov;8(11):1547-50.
<http://www.ncbi.nlm.nih.gov/pubmed/24427938>
- (12) Kaiser S, Dietrich F, de Resende PE et al: Cat's claw oxindole alkaloid isomerization induced by cell incubation and cytotoxic activity against T24 and RT4 human bladder cancer cell lines. *Planta Med*. 2013 Oct;79(15):1413-20. <http://www.ncbi.nlm.nih.gov/pubmed/23975868>

- (13) Shi Z, Lu Z, Zhao Y et al: Neuroprotective effects of aqueous extracts of *Uncaria tomentosa*: Insights from 6-OHDA induced cell damage and transgenic *Caenorhabditis elegans* model. *Neurochem Int.* 2013 Jun;62(7):940-7. <http://www.ncbi.nlm.nih.gov/pubmed/23500604>
- (14) Dreifuss AA, Bastos-Pereira AL, Fabossi IA et al: *Uncaria tomentosa* exerts extensive anti-neoplastic effects against the Walker-256 tumour by modulating oxidative stress and not by alkaloid activity. *PLoS One.* 2013;8(2):e54618. <http://www.ncbi.nlm.nih.gov/pubmed/23408945>
- (15) Mur E, Hartig F, Eibl G, Schirmer M: Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of *uncaria tomentosa* for the treatment of rheumatoid arthritis. *J Rheumatol.* 2002 Apr;29(4):678-81. <http://www.ncbi.nlm.nih.gov/pubmed/11950006>
- (16) Rojas-Duran R, González-Aspajo G, Ruiz-Martel C et al: Anti-inflammatory activity of Mitraphylline isolated from *Uncaria tomentosa* bark. *J Ethnopharmacol.* 2012 Oct 11;143(3):801-4. <http://www.ncbi.nlm.nih.gov/pubmed/22846434>
- (17) Santos Araújo Mdo C, Farias IL, Gutierrez J et al: *Uncaria tomentosa*-Adjuvant Treatment for Breast Cancer: Clinical Trial. *Evid Based Complement Alternat Med.* 2012; 2012:676984. <http://www.ncbi.nlm.nih.gov/pubmed/22811748>
- (18) Bors M, Michałowicz J, Pilarski R et al: Studies of biological properties of *Uncaria tomentosa* extracts on human blood mononuclear cells. *J Ethnopharmacol.* 2012 Aug 1;142(3):669-78. <http://www.ncbi.nlm.nih.gov/pubmed/22683905>
- (19) Akhtar N, Miller MJ, Haqqi TM et al: Effect of a Herbal-Leucine mix on the IL-1 β -induced cartilage degradation and inflammatory gene expression in human chondrocytes. *BMC Complement Altern Med.* 2011 Aug 19;11:66. <http://www.ncbi.nlm.nih.gov/pubmed/21854562>
- (20) Guthrie OW, Gearhart CA, Fulton S et al: Carboxy alkyl esters of *Uncaria tomentosa* augment recovery of sensorineural functions following noise injury. *Brain Res.* 2011 Aug 17;1407:97-106. <http://www.ncbi.nlm.nih.gov/pubmed/21762882>

- (21) Domingues A, Sartori A, Golim MA et al: Prevention of experimental diabetes by *Uncaria tomentosa* extract: Th2 polarization, regulatory T cell preservation or both? *J Ethnopharmacol*. 2011 Sep 1;137(1):635-42. <http://www.ncbi.nlm.nih.gov/pubmed/21718770>
- (22) Bors M, Bukowska B, Pilarski R et al: Protective activity of the *Uncaria tomentosa* extracts on human erythrocytes in oxidative stress induced by 2,4-dichlorophenol (2,4-DCP) and catechol. *Food Chem Toxicol*. 2011 Sep;49(9):2202-11. <http://www.ncbi.nlm.nih.gov/pubmed/21712061>
- (23) Domingues A, Sartori A, Valente LM et al: *Uncaria tomentosa* aqueous-ethanol extract triggers an immunomodulation toward a Th2 cytokine profile. *Phytother Res*. 2011 Aug;25(8):1229-35. <http://www.ncbi.nlm.nih.gov/pubmed/21656603>
- (24) Miller AK, Benson JM, Muanza DN et al: Anti-inflammatory effects of natural product formulations on murine dendritic cells. *J Diet Suppl*. 2011 Mar;8(1):19-33. <http://www.ncbi.nlm.nih.gov/pubmed/21399725>
- (25) Anter J, Romero-Jiménez M, Fernández-Bedmar Z et al: Antigenotoxicity, cytotoxicity, and apoptosis induction by apigenin, bisabolol, and protocatechuic acid. *J Med Food*. 2011 Mar;14(3):276-83. <http://www.ncbi.nlm.nih.gov/pubmed/21182433>
- (26) Gurrola-Díaz CM, García-López PM, Gulewicz K et al: Inhibitory mechanisms of two *Uncaria tomentosa* extracts affecting the Wnt-signaling pathway. *Phytomedicine*. 2011 Jun 15;18(8-9):683-90. <http://www.ncbi.nlm.nih.gov/pubmed/21156346>
- (27) Nogueira Neto J, Coelho TM, Aguiar GC et al: Experimental endometriosis reduction in rats treated with *Uncaria tomentosa* (cat's claw) extract. *Eur J Obstet Gynecol Reprod Biol*. 2011 Feb;154(2):205-8. <http://www.ncbi.nlm.nih.gov/pubmed/21030132>
- (28) Herrera DR, Tay LY, Rezende EC et al: In vitro antimicrobial activity of phytotherapeutic *Uncaria tomentosa* against endodontic pathogens. *J Oral Sci*. 2010 Sep;52(3):473-6. <http://www.ncbi.nlm.nih.gov/pubmed/20881342>

- (29) Pilarski R, Filip B, Wietrzyk J et al: Anticancer activity of the *Uncaria tomentosa* (Willd.) DC. preparations with different oxindole alkaloid composition. *Phytomedicine*. 2010 Dec 1;17(14):1133-9.
<http://www.ncbi.nlm.nih.gov/pubmed/20576410>
- (30) Dreifuss AA, Bastos-Pereira AL, Avila TV et al: Antitumoral and antioxidant effects of a hydroalcoholic extract of cat's claw (*Uncaria tomentosa*) (Willd. Ex Roem. & Schult) in an in vivo carcinosarcoma model. *J Ethnopharmacol*. 2010 Jul 6;130(1):127-33.
<http://www.ncbi.nlm.nih.gov/pubmed/20435132>
- (31) Rinner B, Li ZX, Haas Het al: Antiproliferative and pro-apoptotic effects of *Uncaria tomentosa* in human medullary thyroid carcinoma cells. *Anticancer Res*. 2009 Nov;29(11):4519-28.
<http://www.ncbi.nlm.nih.gov/pubmed/20032400>
- (32) Allen-Hall L, Arnason JT, Cano P et al: *Uncaria tomentosa* acts as a potent TNF-alpha inhibitor through NF-kappaB. *J Ethnopharmacol*. 2010 Feb 17;127(3):685-93. <http://www.ncbi.nlm.nih.gov/pubmed/19995599>
- (33) García Giménez D, García Prado E, Sáenz Rodríguez T et al: Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from *Uncaria tomentosa* bark on human Ewing's sarcoma and breast cancer cell lines. *Planta Med*. 2010 Feb;76(2):133-6.
<http://www.ncbi.nlm.nih.gov/pubmed/19724995>
- (34) Zeng K, Thompson KE, Yates CR et al: Synthesis and biological evaluation of quinic acid derivatives as anti-inflammatory agents. *Bioorg Med Chem Lett*. 2009 Sep 15;19(18):5458-60.
<http://www.ncbi.nlm.nih.gov/pubmed/19674895>
- (35) Amaral S, Mira L, Nogueira JM et al: Plant extracts with anti-inflammatory properties--a new approach for characterization of their bioactive compounds and establishment of structure-antioxidant activity relationships. *Bioorg Med Chem*. 2009 Mar 1;17(5):1876-83.
<http://www.ncbi.nlm.nih.gov/pubmed/19201196>
- (36) Paniagua-Pérez R, Madrigal-Bujaidar E, Molina-Jasso D et al: Antigenotoxic, antioxidant and lymphocyte induction effects produced by

pteropodine. *Basic Clin Pharmacol Toxicol*. 2009 Mar;104(3):222-7.
<http://www.ncbi.nlm.nih.gov/pubmed/19175366>

(37) Reis SR, Valente LM, Sampaio AL et al: Immunomodulating and antiviral activities of *Uncaria tomentosa* on human monocytes infected with Dengue Virus-2. *Int Immunopharmacol*. 2008 Mar;8(3):468-76.
<http://www.ncbi.nlm.nih.gov/pubmed/18279801>

(38) Pilarski R, Poczekaj-Kostrzewska M, Ciesiołka D et al: Antiproliferative activity of various *Uncaria tomentosa* preparations on HL-60 promyelocytic leukemia cells. *Pharmacol Rep*. 2007 Sep-Oct;59(5):565-72.
<http://www.ncbi.nlm.nih.gov/pubmed/18048957>

(39) Cheng AC, Jian CB, Huang YT et al: Induction of apoptosis by *Uncaria tomentosa* through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells. *Food Chem Toxicol*. 2007 Nov;45(11):2206-18.
<http://www.ncbi.nlm.nih.gov/pubmed/17619071>

(40) Ccahuana-Vasquez RA, Santos SS, Koga-Ito CY et al: Antimicrobial activity of *Uncaria tomentosa* against oral human pathogens. *Braz Oral Res*. 2007 Jan-Mar;21(1):46-50. <http://www.ncbi.nlm.nih.gov/pubmed/17426895>

(41) García Prado E, García Gimenez MD, De la Puerta Vázquez R et al: Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloid of *Uncaria tomentosa* on human glioma and neuroblastoma cell lines. *Phytomedicine*. 2007 Apr;14(4):280-4.
<http://www.ncbi.nlm.nih.gov/pubmed/17296291>

(42) Frackowiak T, Baczek T, Roman K et al: Binding of an oxindole alkaloid from *Uncaria tomentosa* to amyloid protein (A β 1-40). *Z Naturforsch C*. 2006 Nov-Dec;61(11-12):821-6.
<http://www.ncbi.nlm.nih.gov/pubmed/17294693>

(43) Hardin SR: Cat's claw: an Amazonian vine decreases inflammation in osteoarthritis. *Complement Ther Clin Pract*. 2007 Feb;13(1):25-8.
<http://www.ncbi.nlm.nih.gov/pubmed/17210508>

(44) Gonzales GF, Valerio LG Jr: Medicinal plants from Peru: a review of plants as potential agents against cancer. *Anticancer Agents Med Chem*. 2006 Sep;6(5):429-44. Review. <http://www.ncbi.nlm.nih.gov/pubmed/17017852>

(45) Allen-Hall L, Cano P, Arnason JT et al: Treatment of THP-1 cells with *Uncaria tomentosa* extracts differentially regulates the expression of IL-1beta and TNF-alpha. *J Ethnopharmacol*. 2007 Jan 19;109(2):312-7. <http://www.ncbi.nlm.nih.gov/pubmed/16959454>

(46) Spelman K, Burns J, Nichols D et al: Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. *Altern Med Rev*. 2006 Jun;11(2):128-50. Review. <http://www.ncbi.nlm.nih.gov/pubmed/16813462>

(47) De Martino L, Martinot JL, Franceschelli S et al: Proapoptotic effect of *Uncaria tomentosa* extracts. *J Ethnopharmacol*. 2006 Aug 11;107(1):91-4. <http://www.ncbi.nlm.nih.gov/pubmed/16569487>

(48) Mammone T, Akesson C, Gan D et al: A water soluble extract from *Uncaria tomentosa* (Cat's Claw) is a potent enhancer of DNA repair in primary organ cultures of human skin. *Phytother Res*. 2006 Mar;20(3):178-83. <http://www.ncbi.nlm.nih.gov/pubmed/16521105>

(49) Bacher N, Tiefenthaler M, Sturm S et al: Oxindole alkaloids from *Uncaria tomentosa* induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells. *Br J Haematol*. 2006 Mar;132(5):615-22. <http://www.ncbi.nlm.nih.gov/pubmed/16445836>

(50) Pilarski R, Zieliński H, Ciesiołka D et al: Antioxidant activity of ethanolic and aqueous extracts of *Uncaria tomentosa* (Willd.) DC. *J Ethnopharmacol*. 2006 Mar 8;104(1-2):18-23. <http://www.ncbi.nlm.nih.gov/pubmed/16202551>

(51) Styczynski J, Wysocki M; Alternative medicine remedies might stimulate viability of leukemic cells. *Pediatr Blood Cancer*. 2006 Jan;46(1):94-8. <http://www.ncbi.nlm.nih.gov/pubmed/16047362>

(52) García R, Cayunao C, Bocic R et al: Antimicrobial activity of isopteropodine. *Z Naturforsch C*. 2005 May-Jun;60(5-6):385-8. <http://www.ncbi.nlm.nih.gov/pubmed/16042336>

(53) Romero-Jiménez M, Campos-Sánchez J, Analla M et al: Genotoxicity and anti-genotoxicity of some traditional medicinal herbs. *Mutat Res.* 2005 Aug 1;585(1-2):147-55. <http://www.ncbi.nlm.nih.gov/pubmed/16005256>.

(54) Setty AR, Sigal LH: Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. *Semin Arthritis Rheum.* 2005 Jun;34(6):773-84. Review. <http://www.ncbi.nlm.nih.gov/pubmed/15942912>

(55) Eberlin S, dos Santos LM, Queiroz ML: Uncaria tomentosa extract increases the number of myeloid progenitor cells in the bone marrow of mice infected with *Listeria monocytogenes*. *Int Immunopharmacol.* 2005 Jul;5(7-8):1235-46. <http://www.ncbi.nlm.nih.gov/pubmed/15914328>

(56) Jürgensen S, Dalbó S, Angers P et al: Involvement of 5-HT₂ receptors in the antinociceptive effect of *Uncaria tomentosa*. *Pharmacol Biochem Behav.* 2005 Jul;81(3):466-77. <http://www.ncbi.nlm.nih.gov/pubmed/15907989>

(57) Gonçalves C, Dinis T, Batista MT: Antioxidant properties of proanthocyanidins of *Uncaria tomentosa* bark decoction: a mechanism for anti-inflammatory activity. *Phytochemistry.* 2005 Jan;66(1):89-98. <http://www.ncbi.nlm.nih.gov/pubmed/15649515>

(58) Heitzman ME, Neto CC, Winiarz E et al: Ethnobotany, phytochemistry and pharmacology of *Uncaria* (Rubiaceae). *Phytochemistry.* 2005 Jan;66(1):5-29. Review. <http://www.ncbi.nlm.nih.gov/pubmed/15649507>

(59) Sheng Y, Akesson C, Holmgren K et al: An active ingredient of Cat's Claw water extracts identification and efficacy of quinic acid. *J Ethnopharmacol.* 2005 Jan 15;96(3):577-84. <http://www.ncbi.nlm.nih.gov/pubmed/15619581>

(60) Cisneros FJ, Jayo M, Niedziela L: An *Uncaria tomentosa* (cat's claw) extract protects mice against ozone-induced lung inflammation. *J Ethnopharmacol.* 2005 Jan 15;96(3):355-64. <http://www.ncbi.nlm.nih.gov/pubmed/15619552>

(61) Akesson C, Lindgren H, Pero RW et al: Quinic acid is a biologically active component of the *Uncaria tomentosa* extract C-Med 100. *Int*

Immunopharmacol. 2005 Jan;5(1):219-29.

<http://www.ncbi.nlm.nih.gov/pubmed/15589483>

(62) Deharo E, Baelmans R, Gimenez A et al: In vitro immunomodulatory activity of plants used by the Tacana ethnic group in Bolivia. *Phytomedicine*. 2004 Sep;11(6):516-22. <http://www.ncbi.nlm.nih.gov/pubmed/15500263>

(63) Winkler C, Wirleitner B, Schroecksnadel K et al: In vitro effects of two extracts and two pure alkaloid preparations of *Uncaria tomentosa* on peripheral blood mononuclear cells. *Planta Med*. 2004 Mar;70(3):205-10. <http://www.ncbi.nlm.nih.gov/pubmed/15114496>

(64) Akesson C, Lindgren H, Pero RW et al: An extract of *Uncaria tomentosa* inhibiting cell division and NF-kappa B activity without inducing cell death. *Int Immunopharmacol*. 2003 Dec;3(13-14):1889-900. <http://www.ncbi.nlm.nih.gov/pubmed/14636838>

(65) Akesson Ch, Pero RW, Ivars F: C-Med 100, a hot water extract of *Uncaria tomentosa*, prolongs lymphocyte survival in vivo. *Phytomedicine*. 2003 Jan;10(1):23-33. <http://www.ncbi.nlm.nih.gov/pubmed/12622460>

(66) Kang TH, Matsumoto K, Tohda M et al: Pteropodine and isopteropodine positively modulate the function of rat muscarinic M(1) and 5-HT(2) receptors expressed in *Xenopus* oocyte. *Eur J Pharmacol*. 2002 May 24;444(1-2):39-45. <http://www.ncbi.nlm.nih.gov/pubmed/12191580>

(67) Sandoval M, Okuhama NN, Zhang XJ et al: Anti-inflammatory and antioxidant activities of cat's claw (*Uncaria tomentosa* and *Uncaria guianensis*) are independent of their alkaloid content. *Phytomedicine*. 2002 May;9(4):325-37. <http://www.ncbi.nlm.nih.gov/pubmed/12120814>

(68) Aguilar JL, Rojas P, Marcelo A et al: Anti-inflammatory activity of two different extracts of *Uncaria tomentosa* (Rubiaceae). *J Ethnopharmacol*. 2002 Jul;81(2):271-6. <http://www.ncbi.nlm.nih.gov/pubmed/12065162>

(69) Mur E, Hartig F, Eibl G et al: Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of *uncaria tomentosa* for the treatment of rheumatoid arthritis. *J Rheumatol*. 2002 Apr;29(4):678-81. <http://www.ncbi.nlm.nih.gov/pubmed/11950006>

(70) Williams JE: Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de Grado. *Altern Med Rev.* 2001 Dec;6(6):567-79. Review. <http://www.ncbi.nlm.nih.gov/pubmed/11804547>

(71) Riva L, Coradini D, Di Fronzo G et al: The antiproliferative effects of *Uncaria tomentosa* extracts and fractions on the growth of breast cancer cell line. *Anticancer Res.* 2001 Jul-Aug;21(4A):2457-61. <http://www.ncbi.nlm.nih.gov/pubmed/11724307>

(72) Piscocoya J, Rodriguez Z, Bustamante SA et al: Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species *Uncaria guianensis*. *Inflamm Res.* 2001 Sep;50(9):442-8. <http://www.ncbi.nlm.nih.gov/pubmed/11603848>

(73) Sheng Y, Li L, Holmgren K et al: DNA repair enhancement of aqueous extracts of *Uncaria tomentosa* in a human volunteer study. *Phytomedicine.* 2001 Jul;8(4):275-82. <http://www.ncbi.nlm.nih.gov/pubmed/11515717>

(74) Lamm S, Sheng Y, Pero RW: Persistent response to pneumococcal vaccine in individuals supplemented with a novel water soluble extract of *Uncaria tomentosa*, C-Med-100. *Phytomedicine.* 2001 Jul;8(4):267-74. <http://www.ncbi.nlm.nih.gov/pubmed/11515716>

(75) Muhammad I, Dunbar DC, Khan RA et al: Investigation of Uña De Gato I. 7-Deoxyloganic acid and ¹⁵N NMR spectroscopic studies on pentacyclic oxindole alkaloids from *Uncaria tomentosa*. *Phytochemistry.* 2001 Jul;57(5):781-5. <http://www.ncbi.nlm.nih.gov/pubmed/11397448>

(76) Muhammad I, Khan IA, Fischer NH et al: Two stereoisomeric pentacyclic oxindole alkaloids from *Uncaria tomentosa*: uncarine C and uncarine E. *Acta Crystallogr C.* 2001 Apr;57(Pt 4):480-2. <http://www.ncbi.nlm.nih.gov/pubmed/11313600>

(77) Mohamed AF, Matsumoto K, Tabata K et al: Effects of *Uncaria tomentosa* total alkaloid and its components on experimental amnesia in mice: elucidation using the passive avoidance test. *J Pharm Pharmacol.* 2000 Dec;52(12):1553-61. <http://www.ncbi.nlm.nih.gov/pubmed/11197086>

(78) Budzinski JW, Foster BC, Vandenhoeck S et al: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine*. 2000 Jul;7(4):273-82.

<http://www.ncbi.nlm.nih.gov/pubmed/10969720>

(79) Sandoval M, Charbonnet RM, Okuhama NN et al: Cat's claw inhibits TNF α production and scavenges free radicals: role in cytoprotection. *Free Radic Biol Med*. 2000 Jul 1;29(1):71-8.

<http://www.ncbi.nlm.nih.gov/pubmed/10962207>

(80) Sheng Y, Pero RW, Wagner H: Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from *Uncaria tomentosa*. *Phytomedicine*. 2000 Apr;7(2):137-43.

<http://www.ncbi.nlm.nih.gov/pubmed/10839217>

(81) Sheng Y, Bryngelsson C, Pero RW: Enhanced DNA repair, immune function and reduced toxicity of C-MED-100, a novel aqueous extract from *Uncaria tomentosa*. *J Ethnopharmacol*. 2000 Feb;69(2):115-26.

<http://www.ncbi.nlm.nih.gov/pubmed/10687868>

(82) Reinhard KH: *Uncaria tomentosa* (Willd.) D.C.: cat's claw, uña de gato, or savéntaro. *J Altern Complement Med*. 1999 Apr;5(2):143-51. Review.

<http://www.ncbi.nlm.nih.gov/pubmed/10328636>

(83) Lemaire I, Assinewe V, Cano P et al: Stimulation of interleukin-1 and -6 production in alveolar macrophages by the neotropical liana, *Uncaria tomentosa* (uña de gato) *J Ethnopharmacol*. 1999

<http://www.ncbi.nlm.nih.gov/pubmed/10197746>

(84) Keplinger K, Laus G, Wurm M et al: *Uncaria tomentosa* (Willd.) DC.--ethnomedicinal use and new pharmacological, toxicological and botanical results. *J Ethnopharmacol*. 1999 Jan;64(1):23-34. Review.

<http://www.ncbi.nlm.nih.gov/pubmed/10075119>

(85) Wurm M, Kacani L, Laus G et al: Pentacyclic oxindole alkaloids from *Uncaria tomentosa* induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. *Planta Med*. 1998 Dec;64(8):701-4.

<http://www.ncbi.nlm.nih.gov/pubmed/9933988>

- (86) Sandoval-Chacón M, Thompson JH et al: Antiinflammatory actions of cat's claw: the role of NF-kappaB. *Aliment Pharmacol Ther.* 1998 Dec;12(12):1279-89. <http://www.ncbi.nlm.nih.gov/pubmed/9882039>
- (87) Sheng Y, Pero RW, Amiri A et al: Induction of apoptosis and inhibition of proliferation in human tumor cells treated with extracts of *Uncaria tomentosa*. *Anticancer Res.* 1998 Sep-Oct;18(5A):3363-8. <http://www.ncbi.nlm.nih.gov/pubmed/9858909>
- (88) Salazar EL, Jayme V: Depletion of specific binding sites for estrogen receptor by *Uncaria tomentosa*. *Proc West Pharmacol Soc.* 1998;41:123-4. <http://www.ncbi.nlm.nih.gov/pubmed/9836266>
- (89) Wirth C, Wagner H: Pharmacologically active procyanidines from the bark of *Uncaria tomentosa*. *Phytomedicine.* 1997 Sep;4(3):265-6. <http://www.ncbi.nlm.nih.gov/pubmed/23195487>
- (90) Santa Maria A, Lopez A, Diaz MM et al: Evaluation of the toxicity of *Uncaria tomentosa* by bioassays in vitro. *J Ethnopharmacol.* 1997 Aug;57(3):183-7. <http://www.ncbi.nlm.nih.gov/pubmed/9292411>
- (91) Rizzi R, Re F, Bianchi A et al: Mutagenic and antimutagenic activities of *Uncaria tomentosa* and its extracts. *J Ethnopharmacol.* 1993 Jan;38(1):63-77. <http://www.ncbi.nlm.nih.gov/pubmed/8479203>
- (92) Aquino R, De Feo V, De Simone F et al: Plant metabolites. New compounds and anti-inflammatory activity of *Uncaria tomentosa*. *J Nat Prod.* 1991 Mar-Apr;54(2):453-9. <http://www.ncbi.nlm.nih.gov/pubmed/1919590>
- (93) Aquino R, De Simone F, Pizza C et al: Plant metabolites. Structure and in vitro antiviral activity of quinovic acid glycosides from *Uncaria tomentosa* and *Guettarda platypoda*. *J Nat Prod.* 1989 Jul-Aug;52(4):679-85. <http://www.ncbi.nlm.nih.gov/pubmed/2553871>
- (94) Senatore A, Cataldo A, Iaccarino FP et al: Phytochemical and biological study of *Uncaria tomentosa*. *Boll Soc Ital Biol Sper.* 1989 Jun;65(6):517-20. Italian. <http://www.ncbi.nlm.nih.gov/pubmed/2611012>

(95) Wagner H, Kreutzkamp B, Jurcic K: The alkaloids of *Uncaria tomentosa* and their phagocytosis-stimulating action. *Planta Med.* 1985 Oct;(5):419-23. German. <http://www.ncbi.nlm.nih.gov/pubmed/4080851>

(96) Pero RW: Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester. USPTO 8,372,449: Feb 12, 2013. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=36&f=G&l=50&d=PTXT&p=1&p=1&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=36&f=G&l=50&d=PTXT&p=1&p=1&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(97) Pero RW: Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester. USPTO 8,372,448: Feb 12, 2013. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=37&f=G&l=50&d=PTXT&p=1&p=1&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=37&f=G&l=50&d=PTXT&p=1&p=1&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(98) Pero RW: Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester. USPTO 7,955,626: Jun 7, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=58&f=G&l=50&d=PTXT&p=1&p=2&S1=%28Uncaria+AND+tomentosa%29&OS=Uncaria+AND+tomentosa&RS=%28Uncaria+AND+tomentosa%29>

(99) Pero RW: Method of preparation and composition of a water soluble extract of the bioactive component of the plant species *Uncaria* for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals. USPTO 7,947,312: May 24, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch->

[adv.htm&r=59&f=G&l=50&d=PTXT&p=1&p=2&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=59&f=G&l=50&d=PTXT&p=1&p=2&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(100) Castillo GM et al: Composition and methods for treating Alzheimer's disease and other amyloidosis. USPTO 7,754,250: Jul 13, 2010.

[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=64&f=G&l=50&d=PTXT&p=1&p=2&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=64&f=G&l=50&d=PTXT&p=1&p=2&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(101) Castillo G et al: Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from *Uncaria tomentosa* and related plants.

USPTO 7,314,642: Jan 1, 2008. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=87&f=G&l=50&d=PTXT&p=1&p=2&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=87&f=G&l=50&d=PTXT&p=1&p=2&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(102) Pero RW: Method of preparation and composition of a water soluble extract of the bioactive component of the plant species *Uncaria* for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals. USPTO 6,964,784: Nov 15, 2005.

[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=96&f=G&l=50&d=PTXT&p=1&p=2&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=96&f=G&l=50&d=PTXT&p=1&p=2&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(103) Bobrowski PJ: Methods and preparations of extracts of *Uncaria* species with reduced alkaloid content. USPTO 6,797,286: Sep 28, 2004.

[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=101&f=G&l=50&d=PTXT&p=1&p=3&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=101&f=G&l=50&d=PTXT&p=1&p=3&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(104) Pero RW: Method of preparation and composition of a water soluble extract of the plant species *uncaria*. USPTO 6,039,949: Mar 21, 2000.

[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=114&f=G&l=50&d=PTXT&p=1&p=3&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnethtml%2FPTO%2Fsearch-adv.htm&r=114&f=G&l=50&d=PTXT&p=1&p=3&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(105) Keplinger K et al: Oxindole alkaloids having properties stimulating the immunologic system & preparation containing the same. USPTO 5,302,611: Apr 12, 1994. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=116&f=G&l=50&d=PTXT&p=1&p=3&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=116&f=G&l=50&d=PTXT&p=1&p=3&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(106) Keplinger K et al: Oxindole alkaloids having properties stimulating the immunologic system and preparation containing the same. USPTO 4,940,725; Jul 10, 1990. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=117&f=G&l=50&d=PTXT&p=1&p=3&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=117&f=G&l=50&d=PTXT&p=1&p=3&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

(107) Keplinger K et al: Oxindole alkaloids having properties stimulating the immunologic system. USPTO 4,844,901: Jul 4, 1989. [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=118&f=G&l=50&d=PTXT&p=1&p=3&S1=\(Uncaria+AND+tomentosa\)&OS=Uncaria+AND+tomentosa&RS=\(Uncaria+AND+tomentosa\)](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=118&f=G&l=50&d=PTXT&p=1&p=3&S1=(Uncaria+AND+tomentosa)&OS=Uncaria+AND+tomentosa&RS=(Uncaria+AND+tomentosa))

Ingredient: Zangrado® and Progrado® - Works Cited

(1) Chordia P, MacArthur RD: Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons. Expert Rev Gastroenterol Hepatol. 2013 Sep;7(7):591-600.

<http://www.ncbi.nlm.nih.gov/pubmed/24070150>

(2) Alonso-Castro AJ, Domínguez F, García-Carrancá A: Rutin exerts antitumor effects on nude mice bearing SW480 tumor. Arch Med Res. 2013 Jul;44(5):346-51. <http://www.ncbi.nlm.nih.gov/pubmed/23867787>

(3) Frampton JE: Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy. *Drugs*. 2013 Jul;73(10):1121-9.

<http://www.ncbi.nlm.nih.gov/pubmed/23807722>

(4) Rossi D, Guerrini A, Paganetto G et al: Croton lechleri Müll. Arg. (Euphorbiaceae) stem bark essential oil as possible mutagen-protective food ingredient against heterocyclic amines from cooked food. *Food Chem*. 2013 Aug 15;139(1-4):439-47. <http://www.ncbi.nlm.nih.gov/pubmed/23561129>

(5) Montopoli M, Bertin R, Chen Z et al: Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines. *J Ethnopharmacol*. 2012 Dec 18;144(3):747-53.

<http://www.ncbi.nlm.nih.gov/pubmed/23123266>

(6) Alonso-Castro AJ, Ortiz-Sánchez E, Domínguez F et al: Antitumor effect of Croton lechleri Mull. Arg. (Euphorbiaceae). *J Ethnopharmacol*. 2012 Mar 27;140(2):438-42. <http://www.ncbi.nlm.nih.gov/pubmed/22301443>

(7) Cottreau J, Tucker A, Crutchley R et al: Crofelemer for the treatment of secretory diarrhea. *Expert Rev Gastroenterol Hepatol*. 2012 Feb;6(1):17-23.

<http://www.ncbi.nlm.nih.gov/pubmed/22301443>

(8) Pereira U, Garcia-Le Gal C, Le Gal G et al: Effects of sangre de drago in an in vitro model of cutaneous neurogenic inflammation. *Exp Dermatol*. 2010 Sep;19(9):796-9. <http://www.ncbi.nlm.nih.gov/pubmed/20698880>

(9) Takami Y, Uto H, Takeshita M et al: Proanthocyanidin derived from the leaves of *Vaccinium virgatum* suppresses platelet-derived growth factor-induced proliferation of the human hepatic stellate cell line LI90. *Hepatol Res*. 2010 Apr;40(4):337-45. <http://www.ncbi.nlm.nih.gov/pubmed/20070402>

(10) Tradtrantip L, Namkung W, Verkman AS: Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from *Croton lechleri*, targets two distinct intestinal chloride channels. *Mol Pharmacol*. 2010 Jan;77(1):69-78. <http://www.ncbi.nlm.nih.gov/pubmed/19808995>

(11) Fayad W, Fryknäs M, Brnjic S et al: Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux

transporters. PLoS One. 2009 Oct 2;4(10):e7238.
<http://www.ncbi.nlm.nih.gov/pubmed/19798419>

(12) Froldi G, Zagotto G, Filippini R et al: Activity of sap from *Croton lechleri* on rat vascular and gastric smooth muscles. *Phytomedicine*. 2009 Aug;16(8):768-75. <http://www.ncbi.nlm.nih.gov/pubmed/19406630>

(13) Miller MJ, Reuter BK, Wallace JL et al: A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient. *J Transl Med*. 2008 Jan 18;6:3. <http://www.ncbi.nlm.nih.gov/pubmed/18205911>

(14) De Marino S, Gala F, Zollo F et al: Identification of minor secondary metabolites from the latex of *Croton lechleri* (Muell-Arg) and evaluation of their antioxidant activity. *Molecules*. 2008 Jun 1;13(6):1219-29.
<http://www.ncbi.nlm.nih.gov/pubmed/18596648>

(15) Miller MJ, Bobrowski P, Shukla M et al: Chondroprotective effects of a proanthocyanidin rich Amazonian genonutrient reflects direct inhibition of matrix metalloproteinases and upregulation of IGF-1 production by human chondrocytes. *J Inflamm (Lond)*. 2007 Aug 14;4:16.
<http://www.ncbi.nlm.nih.gov/pubmed/17697350>

(16) Tran CD, Butler RN, Miller MJ: The role of Amazonian herbal medicine Sangre de Grado in *Helicobacter pylori* infection and its association with metallothionein expression. *Helicobacter*. 2006 Apr;11(2):134-5.
<http://www.ncbi.nlm.nih.gov/pubmed/16579844>

(17) Gonzales GF, Valerio LG Jr: Medicinal plants from Peru: a review of plants as potential agents against cancer. *Anticancer Agents Med Chem*. 2006 Sep;6(5):429-44. Review. <http://www.ncbi.nlm.nih.gov/pubmed/17017852>

(18) Miller MJS, Reuter BK, Bobrowski PJ et al (1996): "Mechanistic and Clinical Assessment of Zangrado®, an Extract of the Amazonian Ethnomedicine Sangre de Grado, for the Treatment of Itch" In Gil Yosipovitch, Malcolm W. Greaves, Alan B. Fleischer, Jr & Francis McGlone (Editors) *Itch: Basic Mechanisms and Therapy* (pp. 305-315). New York: Marcel Dekker.
<http://books.google.com/books?id=SzATlwEACAAJ&dq=miller+reuter+bobrowski+Itch&hl=en&sa=X&ei=12EXVJakleW88QHozYEQ&ved=0CCoQ6AEwAg>

(19) Lopes MI, Saffi J, Echeverrigaray S et al: Mutagenic and antioxidant activities of Croton lechleri sap in biological systems. J Ethnopharmacol. 2004 Dec;95(2-3):437-45. <http://www.ncbi.nlm.nih.gov/pubmed/15507372>

(20) Fischer H, Machen TE, Widdicombe JH et al: A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J Ethnopharmacol. 2004 Aug;93(2-3):351-7. <http://www.ncbi.nlm.nih.gov/pubmed/15234776>

(21) Jones K: Review of sangre de drago (Croton lechleri)--a South American tree sap in the treatment of diarrhea, inflammation, insect bites, viral infections, and wounds: traditional uses to clinical research. J Altern Complement Med. 2003 Dec;9(6):877-96. Review. <http://www.ncbi.nlm.nih.gov/pubmed/14736360>

(22) Risco E, Ghia F, Vila R et al: Immunomodulatory activity and chemical characterisation of sangre de drago (dragon's blood) from Croton lechleri. Planta Med. 2003 Sep;69(9):785-94. <http://www.ncbi.nlm.nih.gov/pubmed/14598201>

(23) Rossi D, Bruni R, Bianchi N et al: Evaluation of the mutagenic, antimutagenic and antiproliferative potential of Croton lechleri (Muell. Arg.) latex. Phytomedicine. 2003 Mar;10(2-3):139-44. <http://www.ncbi.nlm.nih.gov/pubmed/12725567>

(24) Sandoval M, Okuhama NN, Clark M et al: Sangre de grado Croton palanostigma induces apoptosis in human gastrointestinal cancer cells. J Ethnopharmacol. 2002 May;80(2-3):121-9. <http://www.ncbi.nlm.nih.gov/pubmed/12007701>

(25) Williams JE: Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de Grado. Altern Med Rev. 2001 Dec;6(6):567-79. Review. <http://www.ncbi.nlm.nih.gov/pubmed/11804547>

(26) Miller MJ, Vergnolle N, McKnight W et al: Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado. J Invest Dermatol. 2001 Sep;117(3):725-30. <http://www.ncbi.nlm.nih.gov/pubmed/11564183>

- (27) Miller MJ, MacNaughton WK, Zhang XJ et al: Treatment of gastric ulcers and diarrhea with the Amazonian herbal medicine sangre de grado. *Am J Physiol Gastrointest Liver Physiol*. 2000 Jul;279(1):G192-200.
<http://www.ncbi.nlm.nih.gov/pubmed/10898763>
- (28) Desmarchelier C, Witting Schaus F, Coussio J et al: Effects of Sangre de Drago from *Croton lechleri* Muell.-Arg. on the production of active oxygen radicals. *J Ethnopharmacol*. 1997 Oct;58(2):103-8.
<http://www.ncbi.nlm.nih.gov/pubmed/9406898>
- (29) Pieters L, De Bruyne T, Van Poel B et al: In vivo wound healing activity of Dragon's Blood (*Croton* spp.), a traditional South American drug, and its constituents. *Phytomedicine*. 1995 Jul;2(1):17-22.
<http://www.ncbi.nlm.nih.gov/pubmed/23196095>
- (30) Phillipson JD: A matter of some sensitivity. *Phytochemistry*. 1995 Apr;38(6):1319-43. Review. <http://www.ncbi.nlm.nih.gov/pubmed/7786474>
- (31) Chen ZP, Cai Y, Phillipson JD: Studies on the anti-tumour, anti-bacterial, and wound-healing properties of dragon's blood. *Planta Med*. 1994 Dec;60(6):541-5. <http://www.ncbi.nlm.nih.gov/pubmed/7809208>
- (32) Ubillas R, Jolad SD, Bruening RC et al: SP-303, an antiviral oligomeric proanthocyanidin from the latex of *Croton lechleri* (Sangre de Drago). *Phytomedicine*. 1994 Sep;1(2):77-106.
<http://www.ncbi.nlm.nih.gov/pubmed/23195881>
- (33) Pieters L, de Bruyne T, Claeys M et al: Isolation of a dihydrobenzofuran lignan from South American dragon's blood (*Croton* spp.) as an inhibitor of cell proliferation. *J Nat Prod*. 1993 Jun;56(6):899-906.
<http://www.ncbi.nlm.nih.gov/pubmed/8350090>
- (34) Itokawa H, Ichihara Y, Mochizuki M et al: A cytotoxic substance from Sangre de Grado. *Chem Pharm Bull (Tokyo)*. 1991 Apr;39(4):1041-2.
<http://www.ncbi.nlm.nih.gov/pubmed/1893488>

(35) Vaisberg AJ, Milla M, Planas MC et al: Taspine is the cicatrizant principle in Sangre de Grado extracted from Croton lechleri. Planta Med. 1989 Apr;55(2):140-3. <http://www.ncbi.nlm.nih.gov/pubmed/2748730>

(36) Perdue GP, Blomster RN, Blake DA et al: South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci. 1979 Jan;68(1):124-6. <http://www.ncbi.nlm.nih.gov/pubmed/758452>

(37) Rozhon EJ et al: Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions. USPTO 8,574,634: Nov 5, 2013. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=3&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(38) Quart BD et al: Method for treatment of constipation-predominant irritable bowel syndrome. USPTO 8,067,041: Nov 29, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=13&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(39) Bobrowski PJ: Method of treating emesis and itch. USPTO 7,883,727: Feb 8, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=15&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(40) Quart BD et al: Method for treatment of constipation-predominant irritable bowel syndrome. USPTO 7,556,83. Jul 7, 2009. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=25&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(41) Rozhon EJ et al: Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer. USPTO 7,341,744: Mar 11, 2008. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch->

[bool.html&r=27&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri](http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=27&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri)

(42) Rozhon EJ et al: Enteric formulations of proanthocyanidin polymer antidiarrheal compositions. USPTO 7,323,195; Jan 29, 2008.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=28&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(43) Bobrowski PJ: Methods and preparations of the latex from the croton species. USPTO 7,208,183: Apr 24, 2007. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=30&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(44) Tempesta MS: Methods for using proanthocyanidin polymers having antiviral activity. USPTO 5,494,661: Feb 27, 1996.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=32&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(45) Winter REK et al: Wound-healing composition and method. USPTO 5,474,782: Dec 12, 1995.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=33&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(46) Tempesta M: Proanthocyanidin polymers having antiviral activity and methods of obtaining same. USPTO 5,211,944: May 18, 1993.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=34&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(47) Lewis WH et al: Wound-healing composition. USPTO 5,156,847: Oct 20, 1992.

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch->

[bool.html&r=35&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri](http://www.ncbi.nlm.nih.gov/pubmed/2748730)

(35) Vaisberg AJ, Milla M, Planas MC et al: Taspine is the cicatrizant principle in Sangre de Grado extracted from Croton lechleri. Planta Med. 1989 Apr;55(2):140-3. <http://www.ncbi.nlm.nih.gov/pubmed/2748730>

(36) Perdue GP, Blomster RN, Blake DA et al: South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci. 1979 Jan;68(1):124-6. <http://www.ncbi.nlm.nih.gov/pubmed/758452>

(37) Rozhon EJ et al: Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions. USPTO 8,574,634: Nov 5, 2013. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(38) Quart BD et al: Method for treatment of constipation-predominant irritable bowel syndrome. USPTO 8,067,041: Nov 29, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=13&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(39) Bobrowski PJ: Method of treating emesis and itch. USPTO 7,883,727: Feb 8, 2011. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=15&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(40) Quart BD et al: Method for treatment of constipation-predominant irritable bowel syndrome. USPTO 7,556,83. Jul 7, 2009. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=25&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(41) Rozhon EJ et al: Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer. USPTO 7,341,744: Mar 11, 2008. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=27&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(42) Rozhon EJ et al: Enteric formulations of proanthocyanidin polymer antidiarrheal compositions. USPTO 7,323,195; Jan 29, 2008. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=28&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(43) Bobrowski PJ: Methods and preparations of the latex from the croton species. USPTO 7,208,183: Apr 24, 2007. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=30&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(44) Tempesta MS: Methods for using proanthocyanidin polymers having antiviral activity. USPTO 5,494,661: Feb 27, 1996. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=32&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(45) Winter REK et al: Wound-healing composition and method. USPTO 5,474,782: Dec 12, 1995. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=33&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(46) Tempesta M: Proanthocyanidin polymers having antiviral activity and methods of obtaining same. USPTO 5,211,944: May 18, 1993. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearchbool.html&r=34&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

(47) Lewis WH et al: Wound-healing composition. USPTO 5,156,847: Oct 20, 1992. <http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetacgi%2FPTO%2Fsearch-bool.html&r=35&f=G&l=50&co1=AND&d=PTXT&s1=Croton&s2=lechleri&OS=Croton+AND+lechleri&RS=Croton+AND+lechleri>

Ingredient: Lutein® - Works Cited

(1) Meyers KJ, Mares JA, Igo RP Jr et al: Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS). Invest Ophthalmol Vis Sci. 2014 Jan 29; 55(1):587-99. <http://www.ncbi.nlm.nih.gov/pubmed/24346170>

(2) Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP et al: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014 Feb; 132(2):142-9. <http://www.ncbi.nlm.nih.gov/pubmed/24310343>

(3) Wang JJ, Buitendijk GH, Roachchina E et al: Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. Ophthalmology. 2014 Mar; 121(3):667-75. <http://www.ncbi.nlm.nih.gov/pubmed/24290803>

(4) Kesse-Guyot E, Andreeva VA, Ducros V et al: Carotenoid-rich dietary patterns during midlife and subsequent cognitive function. Br J Nutr. 2014 Mar 14; 111(5):915-23. <http://www.ncbi.nlm.nih.gov/pubmed/24073964>

(5) Zou ZY, Xu XR, Lin XM et al: Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2014 Feb; 111(3):474-80. <http://www.ncbi.nlm.nih.gov/pubmed/24047757>

- (6) Slattery ML, Lundgreen A, Wolff RK: Dietary influence on MAPK-signaling pathways and risk of colon and rectal cancer. *Nutr Cancer*. 2013; 65(5):729-38. <http://www.ncbi.nlm.nih.gov/pubmed/23859041>
- (7) Lorenzoni F, Giampietri M, Ferri G: Lutein administration to pregnant women with gestational diabetes mellitus is associated to a decrease of oxidative stress in newborns. *Gynecol Endocrinol*. 2013 Oct; 29(10):901-3. <http://www.ncbi.nlm.nih.gov/pubmed/23808391>
- (8) Wang MX, Jiao JH, Li ZY et al: Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers. *Atherosclerosis*. 2013 Apr; 227(2):380-5. <http://www.ncbi.nlm.nih.gov/pubmed/23398944>
- (9) Murray IJ, Makridaki M, van der Veen RL et al: Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. *Invest Ophthalmol Vis Sci*. 2013 Mar 11; 54(3):1781-8. <http://www.ncbi.nlm.nih.gov/pubmed/23385792>
- (10) Yao Y, Qiu QH, Wu XW et al: Lutein supplementation improves visual performance in Chinese drivers: 1-year randomized, double-blind, placebo-controlled study. *Nutrition*. 2013 Jul-Aug; 29(7-8):958-64. <http://www.ncbi.nlm.nih.gov/pubmed/23360692>
- (11) Huang YM, Yan SF, Ma L et al: Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. *Nutrition*. 2013 Feb; 29(2):387-92. <http://www.ncbi.nlm.nih.gov/pubmed/23312760>
- (12) Meinke MC, Friedrich A, Tscherch K et al: Influence of dietary carotenoids on radical scavenging capacity of the skin and skin lipids. *Eur J Pharm Biopharm*. 2013 Jun; 84(2):365-73. <http://www.ncbi.nlm.nih.gov/pubmed/23246796>
- (13) Beatty S, Chakravarthy U, Nolan JM et al: Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. *Ophthalmology*. 2013 Mar; 120(3):600-6. <http://www.ncbi.nlm.nih.gov/pubmed/23218821>

- (14) Xu XR, Zou ZY, Xiao X et al: Effects of lutein supplement on serum inflammatory cytokines, ApoE and lipid profiles in early atherosclerosis population. *J Atheroscler Thromb.* 2013 Feb 22; 20(2):170-7.
<http://www.ncbi.nlm.nih.gov/pubmed/23154578>
- (15) Berrow EJ, Bartlett HE, Eperjesi F et al: The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy - a randomized controlled trial. *Br J Nutr.* 2013 Jun; 109(11):2008-14.
<http://www.ncbi.nlm.nih.gov/pubmed/23084077>
- (16) Ros MM, Bueno-de-Mesquita HB, Kampman E et al: Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr.* 2012 Oct; 96(4):902-10. <http://www.ncbi.nlm.nih.gov/pubmed/22952186>
- (17) Ma L, Yan SF, Huang YM et al: Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. *Ophthalmology.* 2012 Nov; 119(11):2290-7.
<http://www.ncbi.nlm.nih.gov/pubmed/22858124>
- (18) Ma L, Dou HL, Huang YM et al: Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. *Am J Ophthalmol.* 2012 Oct; 154(4):625-634.
<http://www.ncbi.nlm.nih.gov/pubmed/22835510>
- (19) Giacconi JA, Yu F, Stone KL et al: The association of consumption of fruits/vegetables with decreased risk of glaucoma among older African-American women in the study of osteoporotic fractures. *Am J Ophthalmol.* 2012 Oct; 154(4):635-44. <http://www.ncbi.nlm.nih.gov/pubmed/22818906>
- (20) Manzoni P, Guardione R, Bonetti P et al: Lutein and zeaxanthin supplementation in preterm very low-birthweight neonates in neonatal intensive care units: a multicenter randomized controlled trial. *Am J Perinatol.* 2013 Jan; 30(1):25-32.
<http://www.ncbi.nlm.nih.gov/pubmed/22773282>

(21) Tanito M, Obana A, Gohto Y et al: Macular pigment density changes in Japanese individuals supplemented with lutein or zeaxanthin: quantification via resonance Raman spectrophotometry and autofluorescence imaging. *Jpn J Ophthalmol.* 2012 Sep; 56(5):488-96.

<http://www.ncbi.nlm.nih.gov/pubmed/22699751>

(22) Landrum J, Bone R, Mendez V et al: Comparison of dietary supplementation with lutein diacetate and lutein: a pilot study of the effects on serum and macular pigment. *Acta Biochim Pol.* 2012; 59(1):167-9.

<http://www.ncbi.nlm.nih.gov/pubmed/22428144>

(23) Graydon R, Hogg RE, Chakravarthy U et al: The effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers. *Br J Nutr.* 2012 Jul; 108(2):334-42.

<http://www.ncbi.nlm.nih.gov/pubmed/22313522>

(24) Piermarocchi S, Saviano S, Parisi V et al: Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. *Eur J Ophthalmol.* 2012 Mar-Apr; 22(2):216-25.

<http://www.ncbi.nlm.nih.gov/pubmed/22009916>

(25) Thyagarajan B, A Meyer K, Smith LJ et al: Serum carotenoid concentrations predict lung function evolution in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am J Clin Nutr.* 2011 Nov; 94(5):1211-8. <http://www.ncbi.nlm.nih.gov/pubmed/21918220>

(26) Shvetsov YB, Hernandez BY, Wilkens LR et al: Plasma micronutrients and the acquisition and clearance of anal human papillomavirus infection: the Hawaii HPV cohort study. *Cancer Res.* 2010 Dec 1; 70(23):9787-97.

<http://www.ncbi.nlm.nih.gov/pubmed/20935226>

(27) Berson EL, Rosner B, Sandberg M et al: Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. *Arch Ophthalmol.* 2010 Apr; 128(4):403-11. <http://www.ncbi.nlm.nih.gov/pubmed/20385935>

(28) Perrone S, Longini M, Marzocchi B et al: Effects of lutein on oxidative stress in the term newborn: a pilot study. *Neonatology.* 2010; 97(1):36-40.

<http://www.ncbi.nlm.nih.gov/pubmed/19590244>

- (29) Cho H, Kim MK, Lee JK et al: Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. *Clin Chem Lab Med*. 2009; 47(8):1005-12.
<http://www.ncbi.nlm.nih.gov/pubmed/19589102>
- (30) Ma L, Lin XM, Zou ZY et al: A 12-week lutein supplementation improves visual function in Chinese people with long- term computer display light exposure. *Br J Nutr*. 2009 Jul; 102(2):186-90.
<http://www.ncbi.nlm.nih.gov/pubmed/19586568>
- (31) McCall DO, McGartland CP, McKinley MC et al: Dietary intake of fruits and vegetables improves microvascular function in hypertensive subjects in a dose-dependent manner. *Circulation*. 2009 Apr 28; 119(16):2153-60.
<http://www.ncbi.nlm.nih.gov/pubmed/19364976>
- (32) Mignone LI, Giovannucci E, Newcomb PA et al: Dietary carotenoids and the risk of invasive breast cancer. *Int J Cancer*. 2009 Jun 15; 124(12):2929-37.
<http://www.ncbi.nlm.nih.gov/pubmed/19330841>
- (33) Johnson EJ, McDonald K, Caldarella SM et al: Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. *Nutr Neurosci*. 2008 Apr; 11(2):75-83.
<http://www.ncbi.nlm.nih.gov/pubmed/18510807>
- (34) Johnson EJ, Chung HY, Caldarella SM et al: The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. *Am J Clin Nutr*. 2008 May; 87(5):1521-9.
<http://www.ncbi.nlm.nih.gov/pubmed/18469279>
- (35) Dherani M, Murthy GV, Gupta SK et al: Blood levels of vitamin C, carotenoids and retinol are inversely associated with cataract in a North Indian population. *Invest Ophthalmol Vis Sci*. 2008 Aug; 49(8):3328-35.
<http://www.ncbi.nlm.nih.gov/pubmed/18421094>
- (36) Moeller SM, Volland R, Tinker L et al: Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-Related Eye Disease Study, an Ancillary Study of the

Women's Health Initiative. Arch Ophthalmol. 2008 Mar; 126(3):354-64.
<http://www.ncbi.nlm.nih.gov/pubmed/18332316>

(37) Palombo P, Fabrizi G, Ruocco V et al: Beneficial long-term effects of combined oral/topical antioxidant treatment with the carotenoids lutein and zeaxanthin on human skin: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2007; 20(4):199-210.
<http://www.ncbi.nlm.nih.gov/pubmed/17446716>

(38) Hozawa A, Jacobs DR Jr, Steffes MW et al: Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study. Clin Chem. 2007 Mar; 53(3):447-55.
<http://www.ncbi.nlm.nih.gov/pubmed/17234732>

(39) Zhao X, Aldini G, Johnson EJ et al: Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Am J Clin Nutr. 2006 Jan; 83(1):163-9.
<http://www.ncbi.nlm.nih.gov/pubmed/16400064>

(40) Kato I, Ren J, Visscher DW et al: Nutritional predictors for cellular nipple aspirate fluid: Nutrition and Breast Health Study. Breast Cancer Res Treat. 2006 May; 97(1):33-9. <http://www.ncbi.nlm.nih.gov/pubmed/16317581>

(41) Coyne T, Ibiebele TI, Baade PD et al: Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr. 2005 Sep; 82(3):685-93.
<http://www.ncbi.nlm.nih.gov/pubmed/16155284>

(42) Morganti P, Fabrizi G, Bruno C: Protective effects of oral antioxidants on skin and eye function. Skinmed. 2004 Nov-Dec; 3(6):310-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15538079>

(43) Richer S, Stiles W, Statkute L et al: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr; 75(4):216-30. <http://www.ncbi.nlm.nih.gov/pubmed/15117055>

Ingredient: Lycopene - Works Cited

(1) Mariani S, Lionetto L, Cavallari M et al: Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. *Int J Mol Sci*. 2014 Jan 21;15(1):1433-40. <http://www.ncbi.nlm.nih.gov/pubmed/24451130>

(2) Daniels JA, Mulligan C, McCance D et al: A randomized controlled trial of increasing fruit and vegetable intake and how this influences the carotenoid concentration and activities of PON-1 and LCAT in HDL from subjects with type 2 diabetes. *Cardiovasc Diabetol*. 2014 Jan 14; 13:16. <http://www.ncbi.nlm.nih.gov/pubmed/24423117>

(3) Datta M, Taylor ML, Frizzell B: Dietary and serum lycopene levels in prostate cancer patients undergoing intensity- modulated radiation therapy. *J Med Food*. 2013 Dec;16(12):1131-7. <http://www.ncbi.nlm.nih.gov/pubmed/24180552>

(4) Kesse-Guyot E, Andreeva VA, Ducros V et al: Carotenoid-rich dietary patterns during midlife and subsequent cognitive function. *Br J Nutr*. 2014 Mar 14;111(5):915-23. <http://www.ncbi.nlm.nih.gov/pubmed/24073964>

(5) Zou ZY, Xu XR, Lin XM et al: Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. *Br J Nutr*. 2014 Feb;111(3):474-80. <http://www.ncbi.nlm.nih.gov/pubmed/24047757>

(6) Chen J, Song Y, Zhang L: Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. *J Nutr Sci Vitaminol (Tokyo)*. 2013;59(3):213-23. <http://www.ncbi.nlm.nih.gov/pubmed/23883692>

(7) Morgia G, Cimino S, Favilla V et al: Effects of *Serenoa repens*, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic

and Genital Disease), a multicentre Italian study. *Int Braz J Urol.* 2013 Mar-Apr;39(2):214-21. <http://www.ncbi.nlm.nih.gov/pubmed/23683667>

(8) Sarkar PD, Gupt T, Sahu A Comparative analysis of lycopene in oxidative stress. *J Assoc Physicians India.* 2012 Jul;60:17-9. <http://www.ncbi.nlm.nih.gov/pubmed/23405535>

(9) Karemore TV, Motwani M: Evaluation of the effect of newer antioxidant lycopene in the treatment of oral submucous fibrosis. *Indian J Dent Res.* 2012 Jul-Aug;23(4):524-8. <http://www.ncbi.nlm.nih.gov/pubmed/23257490>

(10) Garrido M, González-Flores D, Marchena AM et al: A lycopene-enriched virgin olive oil enhances antioxidant status in humans. *J Sci Food Agric.* 2013 Jun;93(8):1820-6. <http://www.ncbi.nlm.nih.gov/pubmed/23225211>

(11) Park E, Stacewicz-Sapuntzakis M, Sharifi R et al: Diet adherence dynamics and physiological responses to a tomato product whole-food intervention in African-American men. *Br J Nutr.* 2013 Jun 28;109(12):2219-30. <http://www.ncbi.nlm.nih.gov/pubmed/23200261>

(12) Ghavipour M, Saedisomeolia A, Djalali M et al: Tomato juice consumption reduces systemic inflammation in overweight and obese females. *Br J Nutr.* 2013 Jun;109(11):2031-5. <http://www.ncbi.nlm.nih.gov/pubmed/23069270>

(13) Wood LG, Garg ML, Smart JM et al: Manipulating antioxidant intake in asthma: a randomized controlled trial. *Am J Clin Nutr.* 2012 Sep;96(3):534-43. <http://www.ncbi.nlm.nih.gov/pubmed/22854412>

(14) McEneny J, Wade L, Young IS et al: Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. *J Nutr Biochem.* 2013 Jan;24(1):163-8. <http://www.ncbi.nlm.nih.gov/pubmed/22819555>

(15) Xaplanteris P, Vlachopoulos C, Pietri P et al: Tomato paste supplementation improves endothelial dynamics and reduces plasma total oxidative status in healthy subjects. *Nutr Res.* 2012 May;32(5):390-4. <http://www.ncbi.nlm.nih.gov/pubmed/22652379>

(16) Harms-Ringdahl M, Jenssen D, Haghdoost S: Tomato juice intake suppressed serum concentration of 8-oxodG after extensive physical activity. *Nutr J*. 2012 May 2;11:29. <http://www.ncbi.nlm.nih.gov/pubmed/22551119>

(17) Saawarn N, Shashikanth MC, Saawarn S et al: Lycopene in the management of oral lichen planus: a placebo-controlled study. *Indian J Dent Res*. 2011 Sep-Oct;22(5):639-43. <http://www.ncbi.nlm.nih.gov/pubmed/22406705>

(18) Burton-Freeman B, Talbot J, Park E et al: Protective activity of processed tomato products on postprandial oxidation and inflammation: a clinical trial in healthy weight men and women. *Mol Nutr Food Res*. 2012 Apr;56(4):622-31. <http://www.ncbi.nlm.nih.gov/pubmed/22331646>

(19) Riccioni G, Scotti L, Di Ilio E et al: Lycopene and preclinical carotid atherosclerosis. *J Biol Regul Homeost Agents*. 2011 Jul-Sep;25(3):435-41. <http://www.ncbi.nlm.nih.gov/pubmed/22023768>

(20) Thyagarajan B, A Meyer K, Smith LJ et al: Serum carotenoid concentrations predict lung function evolution in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Am J Clin Nutr*. 2011 Nov;94(5):1211-8. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192474/>

(21) Magbanua MJ, Roy R, Sosa EV et al: Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. *PLoS One*. 2011;6(9):e24004. <http://www.ncbi.nlm.nih.gov/pubmed/21912659>

(22) Oborna I, Malickova K, Fingerova H et al: A randomized controlled trial of lycopene treatment on soluble receptor for advanced glycation end products in seminal and blood plasma of normospermic men. *Am J Reprod Immunol*. 2011 Sep;66(3):179-84. <http://www.ncbi.nlm.nih.gov/pubmed/21276122>

(23) Kim JY, Paik JK, Kim OY et al: Effects of lycopene supplementation on oxidative stress and markers of endothelial function in healthy men. *Atherosclerosis*. 2011 Mar;215(1):189-95. <http://www.ncbi.nlm.nih.gov/pubmed/21194693>

- (24) Shidfar F, Froghifar N, Vafa M et al: The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. *Int J Food Sci Nutr*. 2011 May;62(3):289-94. <http://www.ncbi.nlm.nih.gov/pubmed/21138408>
- (25) Rizwan M, Rodriguez-Blanco I, Harbottle A et al: Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo: a randomized controlled trial. *Br J Dermatol*. 2011 Jan;164(1):154-62. <http://www.ncbi.nlm.nih.gov/pubmed/20854436>
- (26) Zhang X, Wang Q, Neil B et al: Effect of lycopene on androgen receptor and prostate-specific antigen velocity. *Chin Med J (Engl)*. 2010 Aug;123(16):2231-6. <http://www.ncbi.nlm.nih.gov/pubmed/20819671>
- (27) Mackinnon ES, Rao AV, Josse RG et al: Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women. *Osteoporos Int*. 2011 Apr;22(4):1091-101. <http://www.ncbi.nlm.nih.gov/pubmed/20552330>
- (28) Talvas J, Caris-Veyrat C, Guy L et al: Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. *Am J Clin Nutr*. 2010 Jun;91(6):1716-24. <http://www.ncbi.nlm.nih.gov/pubmed/20392890>
- (29) Puri T, Goyal S, Julka PK et al: Lycopene in treatment of high-grade gliomas: a pilot study. *Neurol India*. 2010 Jan-Feb;58(1):20-3. <http://www.ncbi.nlm.nih.gov/pubmed/20228458>
- (30) Darvin ME, Haag SF, Meinke MC et al: Determination of the influence of IR radiation on the antioxidative network of the human skin. *J Biophotonics*. 2011 Jan;4(1-2):21-9. <http://www.ncbi.nlm.nih.gov/pubmed/20151398>
- (31) Darvin ME, Haag S, Meinke M et al: Radical production by infrared A irradiation in human tissue. *Skin Pharmacol Physiol*. 2010;23(1):40-6. <http://www.ncbi.nlm.nih.gov/pubmed/20090407>
- (32) Tomita LY, Longatto Filho A, Costa MC et al: Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-

income Brazilian women. Brazilian Investigation into Nutrition and Cervical Cancer Prevention (BRINCA) Study Team. *Int J Cancer*. 2010 Feb 1;126(3):703-14. <http://www.ncbi.nlm.nih.gov/pubmed/19642096>

(33) Kramer MS, Kahn SR, Platt RW et al: Antioxidant vitamins, long-chain fatty acids, and spontaneous preterm Epidemiology. 2009 Sep;20(5):707-13. <http://www.ncbi.nlm.nih.gov/pubmed/19568173>

(34) Blume-Peytavi U, Rolland A, Darvin ME et al: Cutaneous lycopene and beta-carotene levels measured by resonance Raman spectroscopy: high reliability and sensitivity to oral lactycopene deprivation and supplementation. *Eur J Pharm Biopharm*. 2009 Sep;73(1):187-94. <http://www.ncbi.nlm.nih.gov/pubmed/19442725>

(35) Di Giacomo C, Acquaviva R, Sorrenti V et al: Oxidative and antioxidant status in plasma of runners: effect of oral supplementation with natural antioxidants. *J Med Food*. 2009 Feb;12(1):145-50. <http://www.ncbi.nlm.nih.gov/pubmed/19298208>

(36) Paran E, Novack V, Engelhard YN et al: The effects of natural antioxidants from tomato extract in treated but uncontrolled hypertensive patients. *Cardiovasc Drugs Ther*. 2009 Apr;23(2):145-51. <http://www.ncbi.nlm.nih.gov/pubmed/19052855>

(37) Devaraj S, Mathur S, Basu A et al: A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. *J Am Coll Nutr*. 2008 Apr;27(2):267-73. <http://www.ncbi.nlm.nih.gov/pubmed/18689558>

(38) Hernández-Valero MA, Thomson CA, Hernández M et al: Comparison of baseline dietary intake of Hispanic and matched non-Hispanic white breast cancer survivors enrolled in the Women's Healthy Eating and Living study. *J Am Diet Assoc*. 2008 Aug;108(8):1323-9. <http://www.ncbi.nlm.nih.gov/pubmed/18656572>

(39) Grainger EM, Schwartz SJ, Wang S et al: A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. *Nutr Cancer*. 2008;60(2):145-54. <http://www.ncbi.nlm.nih.gov/pubmed/18444145>

- (40) Dherani M, Murthy GV, Gupta SK et al: Blood levels of vitamin C, carotenoids and retinol are inversely associated with cataract in a North Indian population. *Invest Ophthalmol Vis Sci*. 2008 Aug;49(8):3328-35. <http://www.ncbi.nlm.nih.gov/pubmed/18421094>
- (41) Wood LG, Garg ML, Powell H et al: Lycopene-rich treatments modify noneosinophilic airway inflammation in asthma: proof of concept. *Free Radic Res*. 2008 Jan;42(1):94-102. <http://www.ncbi.nlm.nih.gov/pubmed/18324527>
- (42) Chandra RV, Prabhuji ML, Roopa DA et al: Efficacy of lycopene in the treatment of gingivitis: a randomised, placebo- controlled clinical trial. *Oral Health Prev Dent*. 2007;5(4):327-36. <http://www.ncbi.nlm.nih.gov/pubmed/18173095>
- (43) Schwarz S, Obermüller-Jevic UC, Hellmis E et al: Lycopene inhibits disease progression in patients with benign prostate hyperplasia. *J Nutr*. 2008 Jan;138(1):49-53. <http://www.ncbi.nlm.nih.gov/pubmed/18156403>
- (44) Neyestani TR, Shariatzadeh N, Gharavi A et al: Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. *J Endocrinol Invest*. 2007 Nov;30(10):833-8. <http://www.ncbi.nlm.nih.gov/pubmed/18075285>
- (45) Vrieling A, Voskuil DW, Bonfrer JM et al: Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. *Am J Clin Nutr*. 2007 Nov;86(5):1456-62. <http://ajcn.nutrition.org/content/86/5/1456>
- (46) Thomson CA, Stendell-Hollis NR, Rock CL et al: Plasma and dietary carotenoids are associated with reduced oxidative stress in women previously treated for breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2007 Oct;16(10):2008-15. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575104/>
- (47) Vaishampayan U, Hussain M, Banerjee M et al: Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutr Cancer*. 2007;59(1):1-7. <http://www.ncbi.nlm.nih.gov/pubmed/17927495>

- (48) Shen YC, Chen SL, Wang CK: Contribution of tomato phenolics to antioxidation and down-regulation of blood lipids. *J Agric Food Chem.* 2007 Aug 8;55(16):6475-81. <http://www.ncbi.nlm.nih.gov/pubmed/17629300>
- (49) Silaste ML, Alfthan G, Aro A et al: Tomato juice decreases LDL cholesterol levels and increases LDL resistance to oxidation. *Br J Nutr.* 2007 Dec;98(6):1251-8. <http://www.ncbi.nlm.nih.gov/pubmed/17617941>
- (50) Neyestani TR, Shariat-Zadeh N, Gharavi A et al: The opposite associations of lycopene and body fat mass with humoral immunity in type 2 diabetes mellitus: a possible role in atherogenesis. *Iran J Allergy Asthma Immunol.* 2007 Jun;6(2):79-87. <http://ijaai.tums.ac.ir/index.php/ijaai/article/view/169>
- (51) Walfisch S, Walfisch Y, Kirilov E et al: Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. *Eur J Cancer Prev.* 2007 Aug;16(4):298-303. <http://www.ncbi.nlm.nih.gov/pubmed/17554202>
- (52) Li Y, Zhang J: Serum concentrations of antioxidant vitamins and carotenoids are low in individuals with a history of attempted suicide. *Nutr Neurosci.* 2007 Feb-Apr;10(1-2):51-8. <http://www.ncbi.nlm.nih.gov/pubmed/17539483>
- (53) Graydon R, Gilchrist SE, Young IS et al: Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial. *Eur J Clin Nutr.* 2007 Oct;61(10):1196-200. <http://www.ncbi.nlm.nih.gov/pubmed/17299493>
- (54) Hozawa A, Jacobs DR Jr, Steffes MW et al: Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) study. *Clin Chem.* 2007 Mar;53(3):447-55. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440581/>
- (55) Kumar A, Bagewadi A, Keluskar V et al: Efficacy of lycopene in the management of oral submucous fibrosis. *Oral Surg Oral Med Oral Pathol*

Oral Radiol Endod. 2007 Feb;103(2):207-13.

<http://www.ncbi.nlm.nih.gov/pubmed/17234537>

(56) Riso P, Brusamolino A, Martinetti A et al: Effect of a tomato drink intervention on insulin-like growth factor (IGF)-1 serum levels in healthy subjects. Nutr Cancer. 2006;55(2):157-62.

<http://www.ncbi.nlm.nih.gov/pubmed/17044770>

(57) Barber NJ, Zhang X, Zhu G et al: Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study. Prostate Cancer Prostatic Dis. 2006;9(4):407-13.

<http://www.ncbi.nlm.nih.gov/pubmed/16983396>

(58) Edinger MS, Koff WJ: Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostate hyperplasia. Braz J Med Biol Res. 2006 Aug;39(8):1115-9.

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000800014&lng=en&nrm=iso&tlng=en

(59) Misra R, Mangi S, Joshi S et al: LycoRed as an alternative to hormone replacement therapy in lowering serum lipids and oxidative stress markers: a randomized controlled clinical trial. J Obstet Gynaecol Res. 2006 Jun;32(3):299-304.

<http://www.ncbi.nlm.nih.gov/pubmed/16764620>

(60) Hozawa A, Jacobs DR Jr, Steffes MW et al: Associations of serum carotenoid concentrations with the development of diabetes and with insulin concentration: interaction with smoking: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol. 2006 May 15;163(10):929-37.

<http://aje.oxfordjournals.org/content/163/10/929.long>

(61) Zhao X, Aldini G, Johnson EJ et al: Modification of lymphocyte DNA damage by carotenoid supplementation in postmenopausal women. Am J Clin Nutr. 2006 Jan;83(1):163-9.

<http://ajcn.nutrition.org/content/83/1/163.long>

(62) Nouraie M, Pietinen P, Kamangar F et al: Fruits, vegetables, and antioxidants and risk of gastric cancer among male smokers. Cancer

Epidemiol Biomarkers Prev. 2005 Sep;14(9):2087-92.
<http://cebp.aacrjournals.org/content/14/9/2087.long>

(63) JACC Study Group: Lung cancer mortality and serum levels of carotenoids, retinol, tocopherols, and folic acid in men and women: a case-control study nested in the JACC Study. J Epidemiol. 2005 Jun;15 Suppl 2:S140-9.
https://www.jstage.jst.go.jp/article/jea/15/Supplement_II/15_Supplement_II_S140/article

(64) JACC Study Group: Updated information on risk factors for lung cancer: findings from the JACC Study. J Epidemiol. 2005 Jun;15 Suppl 2:S134-9.
https://www.jstage.jst.go.jp/article/jea/15/Supplement_II/15_Supplement_II_S134/article

(65) van Breemen RB: How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia? J Nutr. 2005 Aug;135(8):2062S-4S. <http://jn.nutrition.org/content/135/8/2062S.long>

(66) Bub A, Barth SW, Watzl B et al: Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. Br J Nutr. 2005 Mar;93(3):291-7. <http://www.ncbi.nlm.nih.gov/pubmed/15877867>

(67) Ansari MS, Gupta NP: Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol. 2004 Sep-Oct;22(5):415-20.
<http://www.ncbi.nlm.nih.gov/pubmed/15464923>

(68) Singh M, Krishanappa R, Bagewadi A et al: Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncol. 2004 Jul;40(6):591-6.
<http://www.ncbi.nlm.nih.gov/pubmed/15063387>

(69) Olfer'ev AM, Il'ina MV, Berzak NV et al: Effect of lycopene on blood lipoproteids in women with type 2 diabetes mellitus in postmenopause. Vopr Pitan. 2004;73(1):19-23. (Russian).
<http://www.ncbi.nlm.nih.gov/pubmed/15049152>

(70) Tyssandier V, Feillet-Coudray C, Caris-Veyrat C et al: Effect of tomato product consumption on the plasma status of antioxidant microconstituents

and on the plasma total antioxidant capacity in healthy subjects. *J Am Coll Nutr.* 2004 Apr;23(2):148-56. <http://www.ncbi.nlm.nih.gov/pubmed/15047681>

(71) Mayne ST, Cartmel B, Lin H et al: Low plasma lycopene concentration is associated with increased mortality in a cohort of patients with prior oral, pharynx or larynx cancers. *J Am Coll Nutr.* 2004 Feb;23(1):34-42. <http://www.ncbi.nlm.nih.gov/pubmed/14963051>

(72) Astley SB, Hughes DA, Wright AJ et al: DNA damage and susceptibility to oxidative damage in lymphocytes: effects of carotenoids in vitro and in vivo. *Br J Nutr.* 2004 Jan;91(1):53-61. <http://www.ncbi.nlm.nih.gov/pubmed/14748938>

(73) Cardinault N, Tyssandier V, Grolier P et al: Comparison of the postprandial chylomicron carotenoid responses in young and older subjects. *Eur J Nutr.* 2003 Dec;42(6):315-23. <http://www.ncbi.nlm.nih.gov/pubmed/14673604>

(74) Hoppe PP, Krämer K, van den Berg H et al: Synthetic and tomato-based lycopene have identical bioavailability in humans. *Eur J Nutr.* 2003 Oct;42(5):272-8. <http://www.ncbi.nlm.nih.gov/pubmed/14564460>

(75) Watzl B, Bub A, Briviba K et al: Supplementation of a low-carotenoid diet with tomato or carrot juice modulates immune functions in healthy men. *Ann Nutr Metab.* 2003;47(6):255-61. <http://www.ncbi.nlm.nih.gov/pubmed/14520020>

(76) Ansari MS, Gupta NP: A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. *BJU Int.* 2003 Sep;92(4):375-8. <http://www.ncbi.nlm.nih.gov/pubmed/12930422>

(77) Césarini JP, Michel L, Maurette JM et al: Immediate effects of UV radiation on the skin: modification by an antioxidant complex containing carotenoids. *Photodermatol Photoimmunol Photomed.* 2003 Aug;19(4):182-9. <http://www.ncbi.nlm.nih.gov/pubmed/12925189>

(78) Visioli F, Riso P, Grande S et al: Protective activity of tomato products on in vivo markers of lipid oxidation. *Eur J Nutr.* 2003 Aug;42(4):201-6. <http://www.ncbi.nlm.nih.gov/pubmed/12923651>

- (79) Gupta NP, Kumar R: Lycopene therapy in idiopathic male infertility--a preliminary report. *Int Urol Nephrol*. 2002;34(3):369-72.
<http://www.ncbi.nlm.nih.gov/pubmed/12899230>
- (80) Sharma JB, Kumar A, Kumar A et al: Effect of lycopene on pre-eclampsia and intra-uterine growth retardation in primigravidas. *Int J Gynaecol Obstet*. 2003 Jun;81(3):257-62. <http://www.ncbi.nlm.nih.gov/pubmed/12767566>
- (81) JACC Study Group: Serum carotenoids and mortality from lung cancer: a case-control study nested in the Japan Collaborative Cohort (JACC) study. *Cancer Sci*. 2003 Jan;94(1):57-63.
<http://www.ncbi.nlm.nih.gov/pubmed/12708475>
- (82) Djuric Z, Uhley VE, Naegeli L et al: Plasma carotenoids, tocopherols, and antioxidant capacity in a 12-week intervention study to reduce fat and/or energy intakes. *Nutrition*. 2003 Mar;19(3):244-9.
<http://www.ncbi.nlm.nih.gov/pubmed/12620527>
- (83) Hadley CW, Clinton SK, Schwartz SJ: The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. *J Nutr*. 2003 Mar;133(3):727-32. <http://jn.nutrition.org/content/133/3/727.long>
- (84) Heinrich U, Gärtner C, Wiebusch M et al: Supplementation with beta-carotene or a similar amount of mixed carotenoids protects humans from UV-induced erythema. *J Nutr*. 2003 Jan;133(1):98-101.
<http://jn.nutrition.org/content/133/1/98.long>
- (85) Bub A, Barth S, Watzl B et al: Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet. *Eur J Nutr*. 2002 Dec;41(6):237-43. <http://www.ncbi.nlm.nih.gov/pubmed/12474066>
- (86) Arab L, Steck-Scott S, Fleishauer AT: Lycopene and the lung. *Exp Biol Med (Maywood)*. 2002 Nov;227(10):894-9.
<http://www.ncbi.nlm.nih.gov/pubmed/12424331>

(87) Kucuk O, Sarkar FH, Djuric Z et al: Effects of lycopene supplementation in patients with localized prostate cancer. *Exp Biol Med* (Maywood). 2002 Nov;227(10):881-5. <http://www.ncbi.nlm.nih.gov/pubmed/12424329>

(88) Vogt TM, Mayne ST, Graubard BI et al: Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. *Am J Epidemiol*. 2002 Jun 1;155(11):1023-32. <http://aje.oxfordjournals.org/content/155/11/1023.long>

(89) Maruyama C, Imamura K, Oshima S et al: Effects of tomato juice consumption on plasma and lipoprotein carotenoid concentrations and the susceptibility of low density lipoprotein to oxidative modification. *J Nutr Sci Vitaminol* (Tokyo). 2001 Jun;47(3):213-21. <http://www.ncbi.nlm.nih.gov/pubmed/11575576>

(90) Kucuk O, Sarkar FH, Sakr W et al: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Biomarkers Prev*. 2001 Aug;10(8):861-8. <http://www.ncbi.nlm.nih.gov/pubmed/11489752>

(91) Mucci LA, Tamimi R, Lagiou P et al: Are dietary influences on the risk of prostate cancer mediated through the insulin- like growth factor system? *BJU Int*. 2001 Jun;87(9):814-20. <http://www.ncbi.nlm.nih.gov/pubmed/11412218>

(92) Stahl W, Heinrich U, Wiseman S et al: Dietary tomato paste protects against ultraviolet light-induced erythema in humans. *J Nutr*. 2001 May;131(5):1449-51. <http://www.ncbi.nlm.nih.gov/pubmed/11340098>

(93) Neuman I, Nahum H, Ben-Amotz A; Reduction of exercise-induced asthma oxidative stress by lycopene, a natural antioxidant. *Allergy*. 2000 Dec;55(12):1184-9. <http://www.ncbi.nlm.nih.gov/pubmed/11117277>

(94) Chopra M, O'Neill ME, Keogh N et al: Influence of increased fruit and vegetable intake on plasma and lipoprotein carotenoids and LDL oxidation in smokers and nonsmokers. *Clin Chem*. 2000 Nov;46(11):1818-29. <http://www.clinchem.org/content/46/11/1818.long>

(95) Hughes DA, Wright AJ, Finglas PM et al: Effects of lycopene and lutein supplementation on the expression of functionally associated surface molecules on blood monocytes from healthy male nonsmokers. *J Infect Dis*.

2000 Sep;182 Suppl 1:S11-5.

http://jid.oxfordjournals.org/content/182/Supplement_1/S11.long

(96) Torbergson AC, Collins AR : Recovery of human lymphocytes from oxidative DNA damage; the apparent enhancement of DNA repair by carotenoids is probably simply an antioxidant effect. Eur J Nutr. 2000 Apr;39(2):80-5. <http://www.ncbi.nlm.nih.gov/pubmed/10918989>

(97) Upritchard JE, Sutherland WH, Mann JI et al: Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000 Jun;23(6):733-8. <http://care.diabetesjournals.org/content/23/6/733.long>

(98) Riso P, Pinder A, Santangelo A et al: Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage? Am J Clin Nutr. 1999 Apr;69(4):712-8. <http://ajcn.nutrition.org/content/69/4/712.long>

(99) Agarwal S, Rao AV: Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study. Lipids. 1998 Oct;33(10):981-4. <http://www.ncbi.nlm.nih.gov/pubmed/9832077>

Ingredient: Astragalus - Works Cited

(1) Brush J, Mendenhall E, Guggenheim A et al: The effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humans. Phytother Res. 2006 Aug;20(8):687-95. <http://www.ncbi.nlm.nih.gov/pubmed/16807880>

(2) Mao SP, Cheng KL, Zhou YF et al: Modulatory effect of Astragalus membranaceus on Th1/Th2 cytokine in patients with herpes simplex keratitis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 Feb;24(2):121-3. (Chinese). <http://www.ncbi.nlm.nih.gov/pubmed/15015443>

(3) Huang ZQ, Qin NP, Ye W: Effect of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995 Jun;15(6):328-30. (Chinese).

<http://www.ncbi.nlm.nih.gov/pubmed/7549379>

(4) Zhang X, Chen J: The mechanism of astragaloside IV promoting sciatic nerve regeneration. Neural Regen Res. 2013 Aug 25;8(24):2256-65.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146037/>

(5) Chen Z, Cai Y, Zhang W et al: Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med. 2014 Oct;8(4):1253-1258. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151649/>

(6) Qiu YY, Zhu JX, Bian T et al: Protective Effects of Astragaloside IV against Ovalbumin-Induced Lung Inflammation Are Regulated/Mediated by T-bet/GATA-3. Pharmacology. 2014 Aug 28;94(1-2):51-59.

<http://www.ncbi.nlm.nih.gov/pubmed/25171656>

(7) Shao A, Guo S, Tu S et al: Astragaloside IV alleviates early brain injury following experimental subarachnoid hemorrhage in rats. Int J Med Sci. 2014 Aug 8;11(10):1073-81.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135229/>

(8) Yang M, Lin HB, Gong S et al: Effect of Astragalus polysaccharides on expression of TNF- α , IL-1 β and NFATc4 in a rat model of experimental colitis. Cytokine. 2014 Aug 14.

<http://www.sciencedirect.com/science/article/pii/S104346661400475X>

(9) Ip FC, Ng YP, An HJ et al: Cycloastragenol Is a Potent Telomerase Activator in Neuronal Cells: Implications for Depression Management. Neurosignals. 2014 Jul 31;22(1):52-63. <http://www.ncbi.nlm.nih.gov/pubmed/25095809>

(10) Fu J, Wang Z, Huang L et al: Review of the Botanical Characteristics, Phytochemistry, and Pharmacology of Astragalus membranaceus (Huangqi). Phyther Res. 2014 Sep;28(9):1275-83.

<http://www.ncbi.nlm.nih.gov/pubmed/25087616>

(11) Zhang A, Zheng Y, Que Z et al: Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. *J Cancer Res Clin Oncol*. 2014 Jul 1.

<http://www.ncbi.nlm.nih.gov/pubmed/25068786>

(12) Dai H, Jia G, Liu X et al: Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades. *Environ Toxicol Pharmacol*. 2014 Jul;38(1):263-71.

<http://www.ncbi.nlm.nih.gov/pubmed/24975447>

(13) Sun Q, Jia N, Wang W et al: Protective effects of astragaloside IV against amyloid beta₁₋₄₂ neurotoxicity by inhibiting the mitochondrial permeability transition pore opening. *PLoS One*. 2014 Jun 6;9(6):e98866.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048237/>

(14) Gu J, Liu K, Li H et al: Astragalus saponin attenuates the expression of fibrosis-related molecules in irradiated cardiac fibroblasts. *Acta Biochim Biophys Sin (Shanghai)*. 2014 Jun;46(6):492-501.

<http://www.ncbi.nlm.nih.gov/pubmed/24739634>

(15) Guo Q, Sun X, Zhang Z et al: The effect of Astragalus polysaccharide on the Epstein-Barr virus lytic cycle. *Acta Virol*. 2014;58(1):76-80.

<http://www.ncbi.nlm.nih.gov/pubmed/24717032>

(16) Oh HA, Choi HJ, Kim NJ et al: Anti-stress effect of astragaloside IV in immobilized mice. *J Ethnopharmacol*. 2014 May 14;153(3):928-

32. <http://www.ncbi.nlm.nih.gov/pubmed/24709311>

(17) Kim MH, Kim SH, Yang WM: Beneficial effects of Astragaloside IV for hair loss via inhibition of Fas/Fas L- mediated apoptotic signaling. *PLoS One*. 2014 Mar 27;9(3):e92984. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968031/>

(18) Chen X, May B, Di YM et al: Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: a systematic review of effect on BODE index and six minute walk test. *PLoS One*. 2014 Mar

12;9(3):e91830. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951501/>

(19) Yeh TS, Chuang HL, Huang WC et al: Astragalus membranaceus improves exercise performance and ameliorates exercise-induced fatigue in trained mice. *Molecules*. 2014 Mar 3;19(3):2793-807.

<http://www.ncbi.nlm.nih.gov/pubmed/24595275>

(20) Yang J, Wang HX, Zhang YJ et al: Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF- κ B signaling pathway in isoproterenol-induced myocardial hypertrophy. *J Ethnopharmacol*. 2013 Oct 25. pii: S0378-8741(13)00724-

1.<http://www.ncbi.nlm.nih.gov/pubmed/24513635>

(21) Wang B, Chen MZ: Astragaloside IV possesses antiarthritic effect by preventing interleukin 1 β -induced joint inflammation and cartilage damage. *Arch Pharm Res*. 2014 Jun;37(6):793-802.

<http://www.ncbi.nlm.nih.gov/pubmed/24469603>

(22) Yang J, Wang HX, Zhang YJ et al: Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF- κ B signaling pathway in isoproterenol-induced myocardial hypertrophy. *J Ethnopharmacol*. 2013 Dec 12;150(3):1062-70. <http://www.ncbi.nlm.nih.gov/pubmed/24432369>

(23) Jia Y, Zuo D, Li Z et al: Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. *Chem Pharm Bull (Tokyo)*. 2014;62(1):45-53.

<http://www.ncbi.nlm.nih.gov/pubmed/24390491>

(24) Agyemang K, Han L, Liu E et al: Recent Advances in Astragalus membranaceus Anti-Diabetic Research: Pharmacological Effects of Its Phytochemical Constituents. *Evid Based Complement Alternat Med*. 2013;2013:654643. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855992/>

(25) Jin M, Zhao K, Huang Q et al: Structural features and biological activities of the polysaccharides from Astragalus membranaceus. *Int J Biol Macromol*. 2014 Mar;64:257-66. <http://www.ncbi.nlm.nih.gov/pubmed/24325861>

(26) In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa. Jin YM, Xu TM, Zhao YH, Wang YC, Cui MH. *Tumour Biol*. 2014 Mar;35(3):2279-84.

<http://www.ncbi.nlm.nih.gov/pubmed/24272199>

- (27) Wang T, Xuan X, Li M et al: Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells. *Diagn Pathol*. 2013 Oct 24;8:179. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818446/>
- (28) Wang SG, Xu Y, Chen JD et al: Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. *Molecules*. 2013 Oct 16;18(10):12809-19. <http://www.mdpi.com/1420-3049/18/10/12809>
- (29) Yang B, Xiao B, Sun T: Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice. *Int J Biol Macromol*. 2013 Nov;62:287-90. <http://www.ncbi.nlm.nih.gov/pubmed/24060282>
- (30) Ren S, Zhang H, Mu Y et al: Pharmacological effects of Astragaloside IV: a literature review. *J Tradit Chin Med*. 2013 Jun;33(3):413-6. Review. <http://www.journaltcm.com/modules/Journal/contents/stories/133/25.pdf>
- (31) Ma X, Zhang K, Li H et al: Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia. *J Ethnopharmacol*. 2013 Oct 7;149(3):720-8. <http://www.ncbi.nlm.nih.gov/pubmed/23968862>
- (32) Lu L, Wang DT, Shi Y et al: Astragalus polysaccharide improves muscle atrophy from dexamethasone- and peroxide-induced injury in vitro. *Int J Biol Macromol*. 2013 Oct;61:7-16. <http://www.ncbi.nlm.nih.gov/pubmed/23817095>
- (33) Li W, Sun YN, Yan XT et al: NF- κ B inhibitory activity of sucrose fatty acid esters and related constituents from Astragalus membranaceus. *J Agric Food Chem*. 2013 Jul 24;61(29):7081-8. <http://www.ncbi.nlm.nih.gov/pubmed/23815760>
- (34) Li W, Sun YN, Yan XT et al: Flavonoids from Astragalus membranaceus and their inhibitory effects on LPS- stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cells. *Arch Pharm Res*. 2014 Feb;37(2):186-92. <http://www.ncbi.nlm.nih.gov/pubmed/23771500>

(35) Kaczmarczyk-Sedlak I, Wojnar W, Zych M et al: Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis. *Evid Based Complement Alternat Med*. 2013;2013:457052. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666393/>

(36) Li M, Ma RN, Li LH et al: Astragaloside IV reduces cerebral edema post-ischemia/reperfusion correlating the suppression of MMP-9 and AQP4. *Eur J Pharmacol*. 2013 Sep 5;715(1-3):189-95. <http://www.ncbi.nlm.nih.gov/pubmed/23747593>

(37) Qi W, Niu J, Qin Q et al: Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. *Cell Stress Chaperones*. 2014 Jan;19(1):105-14. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857426/>

(38) Wang H, Zhang Y, Xia T et al: Synergistic promotion of blood vessel regeneration by astragaloside IV and ferulic acid from electrospun fibrous mats. *Mol Pharm*. 2013 Jun 3;10(6):2394-403. <http://www.ncbi.nlm.nih.gov/pubmed/23651405>

(39) Lai PK, Chan JY, Wu SB et al: Anti-inflammatory activities of an active fraction isolated from the root of *Astragalus membranaceus* in RAW 264.7 macrophages. *Phytother Res*. 2014 Mar;28(3):395-404. <http://www.ncbi.nlm.nih.gov/pubmed/23640962>

(40) Zhao M, Zhao J, He G et al: Effects of astragaloside IV on action potentials and ionic currents in guinea-pig ventricular myocytes. *Biol Pharm Bull*. 2013;36(4):515-21. https://www.jstage.jst.go.jp/article/bpb/36/4/36_b12-00655/article

(41) Lee DY, Noh HJ, Choi J et al: Anti-inflammatory cycloartane-type saponins of *Astragalus membranaceus*. *Molecules*. 2013 Mar 25;18(4):3725-32. <http://www.mdpi.com/1420-3049/18/4/3725>

(42) Wan CP, Gao LX, Hou LF et al: Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity. *Acta Pharmacol Sin*. 2013 Apr;34(4):522-30. <http://www.ncbi.nlm.nih.gov/pubmed/23524573>

(43) Yang Y, Chin A, Zhang L et al: The role of traditional Chinese medicines in osteogenesis and angiogenesis. *Phytother Res*. 2014 Jan;28(1):1-8.
<http://www.ncbi.nlm.nih.gov/pubmed/23494901>

(44) Gui D, Huang J, Guo Y et al: Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF- κ B-mediated inflammatory genes expression. *Cytokine*. 2013 Mar;61(3):970-7.
<http://www.ncbi.nlm.nih.gov/pubmed/23434274>

(45) Molgora B, Bateman R, Sweeney G et al: Functional assessment of pharmacological telomerase activators in human T cells. *Cells*. 2013 Jan 14;2(1):57-66. <http://www.mdpi.com/2073-4409/2/1/57>

(46) Yang ZC, Qu ZH, Yi MJ et al: Astragalus extract attenuates allergic airway inflammation and inhibits nuclear factor κ B expression in asthmatic mice. *Am J Med Sci*. 2013 Nov;346(5):390-5.
<http://www.ncbi.nlm.nih.gov/pubmed/23267235>

(47) Hong MJ, Ko EB, Park SK et al: Inhibitory effect of Astragalus membranaceus root on matrix metalloproteinase-1 collagenase expression and procollagen destruction in ultraviolet B-irradiated human dermal fibroblasts by suppressing nuclear factor kappa-B activity. *J Pharm Pharmacol*. 2013 Jan;65(1):142-8.
<http://www.ncbi.nlm.nih.gov/pubmed/23215697>

(48) Jin H, Luo Q, Zheng Y et al: CD4⁺CD25⁺Foxp3⁺ T cells contribute to the antiasthmatic effects of Astragalus membranaceus extract in a rat model of asthma. *Int Immunopharmacol*. 2013 Jan;15(1):42-9.
<http://www.ncbi.nlm.nih.gov/pubmed/23186751>

(49) Yan L, Zhou QH: Study on neuroprotective effects of astragalin in rats with ischemic brain injury and its mechanisms. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*. 2012 Jul;28(4):373-7. (Chinese).
<http://www.ncbi.nlm.nih.gov/pubmed/23156741>

(50) Kang SC, Kim HJ, Kim MH: Effects of Astragalus membranaceus with supplemental calcium on bone mineral density and bone metabolism in calcium-deficient ovariectomized rats. *Biol Trace Elem Res*. 2013 Jan;151(1):68-74. <http://www.ncbi.nlm.nih.gov/pubmed/23136088>

(51) Liu J, Zhang JF, Lu JZ et al: Astragalus polysaccharide stimulates glucose uptake in L6 myotubes through AMPK activation and AS160/TBC1D4 phosphorylation. *Acta Pharmacol Sin.* 2013 Jan;34(1):137-45.
<http://www.ncbi.nlm.nih.gov/pubmed/23103623>

(52) Chen W, Xia Y, Zhao X et al: The critical role of Astragalus polysaccharides for the improvement of PPAR α [correction of PPAR α]-mediated lipotoxicity in diabetic cardiomyopathy. *PLoS One.* 2012;7(10):e45541.
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045541>

(53) Zhao J, Yang P, Li F et al: Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis. *PLoS One.* 2012;7(9):e44938.
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044938>

(54) Auyeung KK, Law PC, Ko JK: Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. *Oncol Rep.* 2012 Dec;28(6):2188-94. <http://www.ncbi.nlm.nih.gov/pubmed/23023137>

(55) Du X, Zhao B, Li J et al: Astragalus polysaccharides enhance immune responses of HBV DNA vaccination via promoting the dendritic cell maturation and suppressing Treg frequency in mice. *Int Immunopharmacol.* 2012 Dec;14(4):463-70. <http://www.ncbi.nlm.nih.gov/pubmed/23006659>

(56) Yang C, Ma Z: Expression of inducible nitric oxide synthase in restenosis rats and function of Astragalus membranaceus and Angelica sinensis. *Zhongguo Zhong Yao Za Zhi.* 2012 Jun;37(11):1655-8. (Chinese).
<http://www.ncbi.nlm.nih.gov/pubmed/22994002>

(57) Qin Q, Niu J, Wang Z et al: Astragalus membranaceus Inhibits Inflammation via Phospho-P38 Mitogen- Activated Protein Kinase (MAPK) and Nuclear Factor (NF)- κ B Pathways in Advanced Glycation End Product-Stimulated Macrophages. *Int J Mol Sci.* 2012;13(7):8379-87.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430240/>

- (58) Wang Y, Zhu Y, Gao L et al: Formononetin attenuates IL-1 β -induced apoptosis and NF- κ B activation in INS-1 cells. *Molecules*. 2012 Aug 24;17(9):10052-64. <http://www.mdpi.com/1420-3049/17/9/10052>
- (59) Tian QE, De Li H, Yan M et al: Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro. *BMC Complement Altern Med*. 2012 Jul 11;12:94. <http://www.biomedcentral.com/1472-6882/12/94>
- (60) Qin Q, Niu J, Wang Z et al: Astragalus membranaceus extract activates immune response in macrophages via heparanase. *Molecules*. 2012 Jun 13;17(6):7232-40. <http://www.mdpi.com/1420-3049/17/6/7232>
- (61) Li FL, Li X, Wang YF et al: Astragaloside IV Downregulates β -Catenin in Rat Keratinocytes to Counter LiCl-Induced Inhibition of Proliferation and Migration. *Evid Based Complement Alternat Med*. 2012; 2012:956107. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368212/>
- (62) Lai PK, Chan JY, Cheng L et al: Isolation of anti-inflammatory fractions and compounds from the root of Astragalus membranaceus. *Phytother Res*. 2013 Apr;27(4):581-7. <http://www.ncbi.nlm.nih.gov/pubmed/22693074>
- (63) Kim W, Kim SH, Park SK et al: Astragalus membranaceus ameliorates reproductive toxicity induced by cyclophosphamide in male mice. *Phytother Res*. 2012 Sep;26(9):1418-21. Jun 2. <http://www.ncbi.nlm.nih.gov/pubmed/22674751>
- (64) You Y, Duan Y, Liu SW et al: Anti-atherosclerotic function of Astragali Radix extract: downregulation of adhesion molecules in vitro and in vivo. *BMC Complement Altern Med*. 2012 Apr 26;12:54. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478196/>
- (65) Li Q, Bao JM, Li XL et al: Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma. *Chin Med J (Engl)*. 2012 Mar;125(5):786-93. http://www.cmj.org/ch/reader/view_abstract.aspx?volume=125&issue=5&start_page=786

- (66) Chen CC, Lee HC, Chang JH et al: Chinese Herb Astragalus membranaceus Enhances Recovery of Hemorrhagic Stroke: Double-Blind, Placebo-Controlled, Randomized Study. *Evid Based Complement Alternat Med.* 2012;2012:708452.
<http://www.hindawi.com/journals/ecam/2012/708452/>
- (67) Han XH, Liu P, Zhang YY et al: Astragaloside IV regulates expression of ATP-sensitive potassium channel subunits after ischemia-reperfusion in rat ventricular cardiomyocytes. *J Tradit Chin Med.* 2011 Dec;31(4):321-6.
<http://www.ncbi.nlm.nih.gov/pubmed/22462239>
- (68) He X, Shu J, Xu L et al: Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF- α and IL-1 β production in THP-1 cells. *Molecules.* 2012 Mar 12;17(3):3155-64. <http://www.mdpi.com/1420-3049/17/3/3155>
- (69) Xiong M, He Q, Lai H et al: Astragaloside IV inhibits apoptotic cell death in the guinea pig cochlea exposed to impulse noise. *Acta Otolaryngol.* 2012 May;132(5):467-74. <http://www.ncbi.nlm.nih.gov/pubmed/22217340>
- (70) Huang LH, Yan QJ, Kopparapu NK et al: Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells. *Cell Prolif.* 2012 Feb;45(1):15-21. <http://www.ncbi.nlm.nih.gov/pubmed/22172162>
- (71) Ye MN, Chen HF, Zhou RJ et al: Effects of Astragalus polysaccharide on proliferation and Akt phosphorylation of the basal-like breast cancer cell line. *Zhong Xi Yi Jie He Xue Bao.* 2011 Dec;9(12):1339-46. (Chinese).
<http://www.jcimjournal.com/jim/showAbstrPage.aspx?articleid=jcim20111210>
- (72) Jia R, Cao L, Xu P et al: In vitro and in vivo hepatoprotective and antioxidant effects of Astragalus polysaccharides against carbon tetrachloride-induced hepatocyte damage in common carp (*Cyprinus carpio*). *Fish Physiol Biochem.* 2012 Jun;38(3):871-81.
<http://www.ncbi.nlm.nih.gov/pubmed/22089693>
- (73) Zheng R, Deng Y, Chen Y et al: Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK

pathway. *Phytother Res.* 2012 Jun;26(6):892-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22086717>

(74) Du X, Chen X, Zhao B et al: Astragalus polysaccharides enhance the humoral and cellular immune responses of hepatitis B surface antigen vaccination through inhibiting the expression of transforming growth factor β and the frequency of regulatory T cells. *FEMS Immunol Med Microbiol.* 2011 Nov;63(2):228-35. <http://www.ncbi.nlm.nih.gov/pubmed/22077226>

(75) Yang B, Ji C, Chen X et al: Protective effect of astragaloside IV against matrix metalloproteinase-1 expression in ultraviolet-irradiated human dermal fibroblasts. *Arch Pharm Res.* 2011 Sep;34(9):1553-60.
<http://www.ncbi.nlm.nih.gov/pubmed/21975818>

(76) Zhao LH, Ma ZX, Zhu J et al: Characterization of polysaccharide from *Astragalus radix* as the macrophage stimulator. *Cell Immunol.* 2011;271(2):329-34. <http://www.ncbi.nlm.nih.gov/pubmed/21937031>

(77) Chen R, Shao H, Lin S et al: Treatment with *Astragalus membranaceus* produces antioxidative effects and attenuates intestinal mucosa injury induced by intestinal ischemia-reperfusion in rats. *Am J Chin Med.* 2011;39(5):879-87. <http://www.ncbi.nlm.nih.gov/pubmed/21905279>

(78) Hu XY, Xia RX, Cheng CB et al: Mechanism of apoptosis in human leukemia NB4 cells induced by total astragalosides. *Zhonghua Zhong Liu Za Zhi.* 2011 May;33(5):345-8. (Chinese).
<http://www.ncbi.nlm.nih.gov/pubmed/21875462>

(79) Auyeung KK, Woo PK, Law PC et al: Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. *J Ethnopharmacol.* 2012 Jun 1;141(2):635-41.
<http://www.ncbi.nlm.nih.gov/pubmed/21864667>

(80) Collins RA: A ten-year audit of traditional Chinese medicine and other natural product research published in the Chinese Medical Journal (2000-2009). *Chin Med J (Engl).* 2011 May;124(9):1401-8.
http://www.cmj.org/ch/reader/view_abstract.aspx?volume=124&issue=9&start_page=1401

(81) Zhang L, Liu Q, Lu L et al: Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1 α accumulation via phosphatidylinositol 3-kinase/Akt pathway. *J Pharmacol Exp Ther*. 2011 Aug;338(2):485-91.

<http://jpet.aspetjournals.org/content/338/2/485.long>

(82) Zhang N, Wang XH, Mao SL et al: Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats. *Molecules*. 2011 May 10;16(5):3896-907. <http://www.mdpi.com/1420-3049/16/5/3896>

(83) Li SG, Chen Y, Zhang YQ: Effects of Astragalus polysaccharide on nephritis induced by cationic bovine serum albumin in rats. *Zhong Yao Cai*. 2010 Dec;33(12):1913-6. (Chinese).

<http://www.ncbi.nlm.nih.gov/pubmed/21548372>

(84) Xiong M, Lai H, He Q et al: Astragaloside IV attenuates impulse noise-induced trauma in guinea pig..*Acta Otolaryngol*. 2011 Aug;131(8):809-16.

<http://www.ncbi.nlm.nih.gov/pubmed/21526907>

(85) Shang L, Qu Z, Sun L et al: Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. *J Pharm Pharmacol*. 2011 May;63(5):688-94.

<http://www.ncbi.nlm.nih.gov/pubmed/21492171>

(86) Zhang L, Yang Y, Wang Y et al: Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury. *Pharmazie*. 2011 Feb;66(2):144-50.

<http://www.ncbi.nlm.nih.gov/pubmed/21434579>

(87) Bernardes de Jesus B, Schneeberger K, Vera E, Tejera A et al: The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. *Aging Cell*. 2011 Aug;10(4):604-21.

<http://onlinelibrary.wiley.com/doi/10.1111/j.1474-9726.2011.00700.x/full>

(88) Wang YJ, Yu YR: Protective effects of Astragalus membranaceus on free fatty acid-induced vascular endothelial cell dysfunction. *Sichuan Da Xue Xue Bao Yi Xue Ban*. 2011 Jan;42(1):48-51. (Chinese).

<http://www.ncbi.nlm.nih.gov/pubmed/21355300>

(89) Zhang LJ, Liu HK, Hsiao PC et al: New isoflavonoid glycosides and related constituents from astragali radix (*Astragalus membranaceus*) and their inhibitory activity on nitric oxide production. *J Agric Food Chem*. 2011 Feb 23;59(4):1131-7. <http://www.ncbi.nlm.nih.gov/pubmed/21280630>

(90) Harley CB, Liu W, Blasco M et al: A natural product telomerase activator as part of a health maintenance program. *Rejuvenation Res*. 2011 Feb;14(1):45-56. <http://online.liebertpub.com/doi/pdf/10.1089/rej.2010.1085>

(91) Zhang CL, Kong XL, Chen SX et al: Effect of *Astragalus membranaceus* on the proliferation, osteogenic capacity and structure of periodontal ligament cells in vitro. *Hua Xi Kou Qiang Yi Xue Za Zhi*. 2010 Oct;28(5):556-9. (Chinese). <http://www.ncbi.nlm.nih.gov/pubmed/21179698>

(92) Tang D, He B, Zheng ZG et al: Inhibitory effects of two major isoflavonoids in *Radix Astragali* on high glucose-induced mesangial cells proliferation and AGEs-induced endothelial cells apoptosis. *Planta Med*. 2011 May;77(7):729-32. <http://www.ncbi.nlm.nih.gov/pubmed/21157685>

(93) Li YR, Cao W, Guo J et al: Comparative investigations on the protective effects of rhodioside, ciwujianoside- B and astragaloside IV on radiation injuries of the hematopoietic system in mice. *Phytother Res*. 2011 May;25(5):644-53. <http://www.ncbi.nlm.nih.gov/pubmed/21031634>

(94) Huh JE, Nam DW, Baek YH et al: Formononetin accelerates wound repair by the regulation of early growth response factor-1 transcription factor through the phosphorylation of the ERK and p38 MAPK pathways. *Int Immunopharmacol*. 2011 Jan;11(1):46-54. <http://www.ncbi.nlm.nih.gov/pubmed/20959155>

(95) Li M, Wang W, Xue J et al: Meta-analysis of the clinical value of *Astragalus membranaceus* in diabetic nephropathy. *J Ethnopharmacol*. 2011 Jan 27;133(2):412-9. <http://www.ncbi.nlm.nih.gov/pubmed/20951192>

(96) Jaskelioff M, Muller FL, Paik JH et al: Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature*. 2011 Jan 6;469(7328):102-6. <http://www.ncbi.nlm.nih.gov/pubmed/21113150?dopt=Abstract&holding=np>
g

(97) Effects of astragalus on cardiac function and serum tumor necrosis factor-alpha level in patients with chronic heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Jul;30(7):699-701. (Chinese).

<http://www.ncbi.nlm.nih.gov/pubmed/20929124>

(98) Denzler KL, Waters R, Jacobs BL et al: Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals. PLoS One. 2010 Sep 3;5(9):e12561. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933230/>

(99) Callaway E: Telomerase reverses ageing process. Nature. 28 November 2010 doi:10.1038/news.2010.635

<http://www.nature.com/news/2010/101128/full/news.2010.635.html>

(100) Abbott A: Chromosome protection scoops Nobel. Nature. 2009 Oct 461: 706-707. <http://www.nature.com/news/2009/091005/full/461706a.html>

(101) Ledford H: Minimum telomere length defined for healthy cells. Nature. 2007 Oct 449: 515.

<http://www.nature.com/news/2007/071003/full/449515a.html>

Ingredient: Vinpocetine - Works Cited

(1) Brush J, Mendenhall E, Guggenheim A et al: The effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humans. Phytother Res. 2006 Aug;20(8):687-95. <http://www.ncbi.nlm.nih.gov/pubmed/16807880>.

(2) Jovanović ZB, Pavlović AM, Pekmezović T et al: Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study. Ideggyogy Sz. 2013 Jul 30;66(7-8):263-8. <http://www.ncbi.nlm.nih.gov/pubmed/23971358>

(3) Skoromets AA, Aliev KT, Lalayan TV et al: Cognitive functions and treatment of their impairment in elderly patients with the vertebrobasilar insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(4):18-24. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/23739435>

(4) Tabeeva GR, Azimova luE: The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12 Pt 2):20-30. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/23388602>

(5) Valikovics A, Csányi A, Németh L: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2012 Mar 30;65(3-4):115-20. (Hungarian). <http://www.ncbi.nlm.nih.gov/pubmed/23136730>

(6) Chukanova EI; Efficacy of cavinton in the treatment of patients with chronic blood flow insufficiency. Russian multicenter clinical-epidemiological program "CALIPSO". Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-52. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/21311488>

(7) Gavrilova SI, Kolykhalov IV, Fedorova IaB et al: Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):62-9. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/20436440>

(8) Afon'kin Vlu, Dobretsov KG, Sipkin AV: The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing. Vestn Otorinolaringol. 2009; (6):69-70. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/20081798>

(9) Skoromets AA, Tanashian MM, Chukanova EI et al: A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5 Suppl 2):44-8. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/19894300>

(10) Chukanova EI: Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(9):35-9. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/19770831>

(11) Feher G, Koltai K, Kesmarky G et al: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine. 2009 Mar;16(2-3):111-7. <http://www.ncbi.nlm.nih.gov/pubmed/19135345>

(12) Valikovics A: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10. (Hungarian). <http://www.ncbi.nlm.nih.gov/pubmed/17713111>

(13) Kemény V, Molnár S, Andrejkovics M et al: Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005 Sep;45(9):1048-54. <http://www.ncbi.nlm.nih.gov/pubmed/16100299>

(14) Szilágyi G, Nagy Z, Balkay L et al: Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005 Mar 15;229-230:275-84. <http://www.ncbi.nlm.nih.gov/pubmed/15760651>

(15) Vas A, Christer H, Sóvágó J et al: Human positron emission tomography with oral ¹¹C-vinpocetine]. Orv Hetil. 2003 Nov 16;144(46):2271-6. (Hungarian). <http://www.ncbi.nlm.nih.gov/pubmed/14702922>

(16) Szapáry L, Horváth B, Alexy T et al: Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv Hetil. 2003 May 18;144(20):973-8. (Hungarian). <http://www.ncbi.nlm.nih.gov/pubmed/12830727>

(17) Gulyás B, Halldin C, Sandell J et al: PET studies on the brain uptake and regional distribution of [¹¹C]vinpocetine in human subjects. Acta Neurol Scand. 2002 Dec;106(6):325-32. <http://www.ncbi.nlm.nih.gov/pubmed/12460136>

(18) Gulyás B, Halldin C, Sóvágó J et al: Drug distribution in man: a positron emission tomography study after oral administration of the labelled

neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1031-8. <http://www.ncbi.nlm.nih.gov/pubmed/12173017>

(19) Bönöczk P, Panczel G, Nagy Z: Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91. <http://www.ncbi.nlm.nih.gov/pubmed/12044859>

(20) Kolarov G, Orbetsova M, Nalbanski B et al: Complex effects of cavinton on climacteric symptoms. Akush Ginekol (Sofia). 2001;42(2):37-41. (Bulgarian). <http://www.ncbi.nlm.nih.gov/pubmed/11799757>

(21) Feigin VL, Doronin BM, Popova TF et al: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001 Jan;8(1):81-5. <http://www.ncbi.nlm.nih.gov/pubmed/11509086>

(22) Truss MC, Stief CG, Uckert S et al: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol. 2000 Dec;18(6):439-43. <http://www.ncbi.nlm.nih.gov/pubmed/11204266>

(23) Miyazaki M: The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology. 1995 Jan;46(1):53-8. <http://www.ncbi.nlm.nih.gov/pubmed/7818157>

(24) Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991 Spring;6(1):31-43. <http://www.ncbi.nlm.nih.gov/pubmed/2071888>

(25) Dutov AA, Gal'tvanitsa GA, Volkova VA et al: Cavinton in the prevention of the convulsive syndrome in children after birth injury. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(8):21-2. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/1661506>

(26) Kiss E: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther Hung. 1990;38(4):170-3. <http://www.ncbi.nlm.nih.gov/pubmed/2094056>

(27) Bhatti JZ, Hindmarch I: Vinpocetine effects on cognitive impairments produced by flunitrazepam. *Int Clin Psychopharmacol*. 1987 Oct;2(4):325-31. <http://www.ncbi.nlm.nih.gov/pubmed/3693872>

(28) Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. *J Am Geriatr Soc*. 1987 May;35(5):425-30. <http://www.ncbi.nlm.nih.gov/pubmed/3553281>

(29) Pilgramm M, Schumann K: Need for rheologically active, vasoactive and metabolically active substances in the initial treatment of acute acoustic trauma. *HNO*. 1986 Oct;34(10):424-8. (German). <http://www.ncbi.nlm.nih.gov/pubmed/2432041>

(30) Domżał T, Kozłowski P, Zaleska : Cavinton in the treatment of ischemic cerebral stroke. Clinical and computerized-tomographic evaluation. *Neurol Neurochir Pol*. 1986 May-Jun;20(3):234-40. (Polish). <http://www.ncbi.nlm.nih.gov/pubmed/3537828>

(31) Subhan Z, Hindmarch I: Psychopharmacological effects of vinpocetine in normal healthy volunteers. *Eur J Clin Pharmacol*. 1985;28(5):567-71. <http://www.ncbi.nlm.nih.gov/pubmed/3899677>

(32) Bodo D, Kotovskaia AR, Galle RR et al: Effectiveness of the preparation Gavinton in preventing motion sickness. *Kosm Biol Aviakosm Med*. 1982 May-Jun;16(3):49-51. (Russian). <http://www.ncbi.nlm.nih.gov/pubmed/7098411>

Ingredient: Piperine - Works Cited

(1) Panahi Y, Ghanei M, Hajhashemi A et al: Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial. *J Diet Suppl*. 2014 Aug 29. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/25171552>

(2) Panahi Y, Badeli R, Karami GR et al: Investigation of the Efficacy of Adjunctive Therapy with Bioavailability-Boosted Curcuminoids in Major Depressive Disorder. *Phytother Res.* 2014 Aug 4. doi: 10.1002/ptr.5211. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/25091591>

(3) Rahimnia AR, Panahi Y, Alishiri G et al: Impact of Supplementation with Curcuminoids on Systemic Inflammation in Patients with Knee Osteoarthritis: Findings from a Randomized Double-Blind Placebo- Controlled Trial. *Drug Res (Stuttg).* 2014 Jul 22. [Epub ahead of print] <http://www.ncbi.nlm.nih.gov/pubmed/25050518>

(4) Ajazuddin, Alexander A, Qureshi A et al: Role of herbal bioactives as a potential bioavailability enhancer for Active Pharmaceutical Ingredients. *Fitoterapia.* 2014 Sep;97C:1-14. <http://www.ncbi.nlm.nih.gov/pubmed/24862064>

(5) Wightman EL, Reay JL, Haskell CF et al: Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. *Br J Nutr.* 2014 Jul;112(2):203-13. <http://www.ncbi.nlm.nih.gov/pubmed/24804871>

(6) Feng X, Liu Y, Wang X et al: Effects of piperine on the intestinal permeability and pharmacokinetics of linarin in rats. *Molecules.* 2014 Apr 30;19(5):5624-33. <http://www.mdpi.com/1420-3049/19/5/5624>

(7) Kesarwani K1, Gupta R, Mukerjee A: Bioavailability enhancers of herbal origin: an overview. *Asian Pac J Trop Biomed.* 2013 Apr; 3(4):253-66. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634921/>

PhytoZon® is manufactured and distributed exclusively by American Dream Nutrition, LLC., all rights are reserved.